
Initiate at Buy with a $38 target as cost self-help cushions 2027 margins
We initiate on Dow Inc. at Buy with a $37.84 twelve-month target and a 29% total return including the $1.40 dividend, with Low conviction. Dow converts natural-gas liquids into plastics, polyurethanes and silicones at 91 sites. Operating EBITDA (earnings before interest, tax, depreciation, amortisation and one-off items) reaches $6.4bn in FY27E.
- Retained cost self-help adds $8 a share at mid-cycle (about $4.60 after the slower path to mid-cycle). Transform to Outperform cuts and European closures deliver $1.1bn in FY27E and leave $0.9bn of lasting mid-cycle operating EBITDA.
- US ethane feedstock cushions the 2027 polyethylene reset. US Gulf Coast crackers running above 90% hold FY27E polyethylene give-back to 4¢/lb versus about 8¢/lb in consensus.
- Working-capital release restores cash conversion ahead of Path2Zero. Cash conversion rebounds to 87% in FY26E and holds near 75% from FY28E, while Path2Zero (Fort Saskatchewan, Alberta) adds $3.70 a share of net present value (NPV).
What the market is missing. Consensus models $5.5bn of FY27E operating EBITDA and $1.84 of operating earnings per share (EPS), below the third-quarter run-rate despite $1.3bn of guided self-help. We sit 16% and 56% higher.
Catalysts. Late-2026 polyethylene contract settlements (+12¢/lb nominated), the FY27 bridge at fourth-quarter 2026 results in late January 2027, Sadara talks and European shutdowns test our call.
Valuation and target. We value Dow at 6.75x mid-cycle operating EBITDA of $7.6bn, add $2.7bn for Path2Zero and deduct $25.3bn of debt and other claims. That gives a base value of about $40 a share. Weighting the bull, base and bear cases gives $36 today, which rolls forward to our $37.84 target. A one-point rise in the weighted average cost of capital (WACC) would make it a Hold.
Risks. A reset to FY23–FY25 trough margins cuts value by $16 a share, lost self-help costs $7, and a Middle East oil unwind costs $1.30.
| Dec YE, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Net sales | 42,964 | 39,968 | 44,033 | 43,115 | 43,977 |
| Growth y/y | −3.7% | −7.0% | +10.2% | −2.1% | +2.0% |
| Operating EBITDA | 5,482 | 3,256 | 6,288 | 6,434 | 6,817 |
| Margin | 12.8% | 8.1% | 14.3% | 14.9% | 15.5% |
| Operating net income | 1,206 | −662 | 1,967 | 2,072 | 2,399 |
| Operating EPS ($) | 1.71 | −0.93 | 2.71 | 2.87 | 3.44 |
| Growth y/y | −23.7% | n.m. | n.m. | +5.9% | +20.0% |
| Free cash flow | −26 | −1,417 | 2,962 | 1,968 | 2,398 |
| At $30.37, 18 Nov 26 | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Price / earnings (P/E) | 17.8x | n.m. | 11.2x | 10.6x | 8.8x |
| EV / Op. EBITDA | 8.3x | 13.9x | 7.2x | 7.1x | 6.7x |
| Price / book (P/B) | 1.2x | 1.4x | 1.4x | 1.3x | 1.3x |
| Free cash flow (FCF) yield | −0.1% | −6.6% | 13.4% | 9.0% | 11.3% |
| Dividend yield | 9.2% | 6.9% | 4.6% | 4.6% | 4.6% |
| Return on equity (ROE) | 6.7% | −4.0% | 12.2% | 12.6% | 14.4% |
| Net debt / Op. EBITDA | 2.6x | 4.4x | 2.1x | 2.0x | 1.9x |
| P/E at our target | 22.1x | n.m. | 14.0x | 13.2x | 11.0x |
Source: Company filings; Penmark Research model. Right: multiples at the 18 Nov 2026 close ($30.37; diluted market cap $22,091m; full-bridge EV $45,389m excluding the recovery-path charge, which is the present value of the after-tax profit shortfall below mid-cycle, 4Q26E to FY30E); only the final row is at our $37.84 target. Shaded columns are estimates (E); n.m. = not meaningful.
Base value is about $40 a share (+31%), but bear-case downside outweighs base-case upside
Source: Company filings; Yahoo Finance; Penmark Research model. Fan endpoints show 12m rolled values ($53.35 / $41.68 / $16.97).
Oct/Nov polyethylene (PE) hikes hold; 100% self-help ($8.6bn normalised EBITDA) at 6.75x; Sadara settles at $1.0bn.
PE fades 4¢/lb in FY27E; 85% self-help and 50% Transform to Outperform (T2O) kept ($7.6bn EBITDA) at 6.75x plus Path2Zero.
FY23–FY25 trough margin (11.0%) becomes mid-cycle ($5.2bn EBITDA); self-help competed away; Sadara called.
| Income statement, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Net sales | 42,964 | 39,968 | 44,033 | 43,115 | 43,977 |
| Operating EBITDA | 5,482 | 3,256 | 6,288 | 6,434 | 6,817 |
| Operating EBITDA margin | 12.8% | 8.1% | 14.3% | 14.9% | 15.5% |
| Depreciation & amort. | −2,894 | −2,834 | −2,719 | −2,726 | −2,717 |
| Operating EBIT | 2,588 | 422 | 3,569 | 3,707 | 4,100 |
| Net interest expense | −611 | −713 | −670 | −667 | −640 |
| Operating tax & NCI | −771 | −371 | −932 | −969 | −1,061 |
| Operating net income | 1,206 | −662 | 1,967 | 2,072 | 2,399 |
| GAAP net income to Dow | 1,116 | −2,623 | 982 | 1,623 | 2,282 |
| Cash flow, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Operating EBITDA | 5,482 | 3,256 | 6,288 | 6,434 | 6,817 |
| Working capital, tax & int. | −2,568 | −2,194 | −825 | −1,815 | −1,669 |
| Operating cash flow | 2,914 | 1,062 | 5,463 | 4,618 | 5,148 |
| Capital expenditures | −2,940 | −2,479 | −2,501 | −2,650 | −2,750 |
| Free cash flow | −26 | −1,417 | 2,962 | 1,968 | 2,398 |
| Dividends to Dow & NCI | −1,966 | −1,490 | −1,315 | −1,316 | −1,310 |
| Share buybacks | −494 | 0 | 0 | −230 | −1,088 |
| Net borrowing & other financing | 1,688 | 4,534 | −1,330 | −1,255 | 0 |
| Change in cash | −798 | 1,627 | 317 | −833 | 0 |
| Balance sheet, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Cash and equivalents | 2,189 | 3,816 | 4,133 | 3,300 | 3,300 |
| Trade working capital | 6,453 | 7,206 | 7,514 | 7,545 | 7,696 |
| Net property (PP&E) | 22,004 | 22,250 | 22,428 | 22,499 | 22,661 |
| Goodwill & intangibles | 10,286 | 9,464 | 9,223 | 9,076 | 8,946 |
| Net invested assets | 38,819 | 40,377 | 39,370 | 38,492 | 38,675 |
| Gross debt | 16,343 | 18,161 | 17,339 | 16,084 | 16,084 |
| Net debt | 14,154 | 14,345 | 13,206 | 12,784 | 12,784 |
| Stockholders’ equity | 17,355 | 16,008 | 16,234 | 16,611 | 16,795 |
| Per share & KPIs | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Diluted shares (m) | 705.1 | 711.6 | 725.5 | 721.8 | 696.4 |
| Operating EPS ($) | 1.71 | −0.93 | 2.71 | 2.87 | 3.44 |
| GAAP diluted EPS ($) | 1.57 | −3.70 | 1.35 | 2.25 | 3.28 |
| Dividend per share ($) | 2.80 | 2.10 | 1.40 | 1.40 | 1.40 |
| FCF per share ($) | −0.04 | −1.99 | 4.08 | 2.73 | 3.44 |
| Book value per share ($) | 24.61 | 22.50 | 22.38 | 23.01 | 24.12 |
| P&SP Op. EBITDA ($m) | 3,856 | 2,266 | 4,263 | 4,107 | n.a. |
| Cash conversion (%) | 53.2% | 32.6% | 86.9% | 71.8% | 75.5% |
Source: Company Form 10-K and 10-Q filings; Penmark Research model. Shaded columns are estimates (E); n.a. = not available or not modelled separately after FY27E. Operating EBITDA and operating net income exclude restructuring, impairment and litigation charges; noncontrolling interests (NCI) and postretirement obligations are deducted separately in our equity bridge.
Margins recover to about 15% by FY28E; our FY27E EPS is 56% above the Street
| Growth, margins (%) | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Growth y/y | |||||
| Net sales | −3.7% | −7.0% | +10.2% | −2.1% | +2.0% |
| Operating EBITDA | +1.7% | −40.6% | +93.1% | +2.3% | +6.0% |
| Operating EBIT | −6.8% | −83.7% | +746% | +3.9% | +10.6% |
| Operating EPS | −23.7% | n.m. | n.m. | +5.9% | +20.0% |
| Dividend per share | 0.0% | −25.0% | −33.3% | 0.0% | 0.0% |
| Margins and coverage | |||||
| Cash conversion | 53.2% | 32.6% | 86.9% | 71.8% | 75.5% |
| Operating EBITDA margin | 12.8% | 8.1% | 14.3% | 14.9% | 15.5% |
| Operating EBIT margin | 6.0% | 1.1% | 8.1% | 8.6% | 9.3% |
| FCF margin | −0.1% | −3.5% | 6.7% | 4.6% | 5.5% |
| Op. EBITDA / net interest | 9.0x | 4.6x | 9.4x | 9.6x | 10.7x |
| Capex / net sales | 6.8% | 6.2% | 5.7% | 6.1% | 6.3% |
| Ratios and valuation | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Returns and leverage | |||||
| Operating ROE | 6.7% | −4.0% | 12.2% | 12.6% | 14.4% |
| Operating ROA (net assets) | 3.1% | −1.7% | 4.9% | 5.3% | 6.2% |
| After-tax operating ROIC | 6.3% | 1.0% | 9.0% | 9.4% | 10.3% |
| Net debt / equity | 81.6% | 89.6% | 81.3% | 77.0% | 76.1% |
| Net debt / Op. EBITDA | 2.6x | 4.4x | 2.1x | 2.0x | 1.9x |
| Valuation at $30.37 (18 Nov 2026) | |||||
| P/E | 17.8x | n.m. | 11.2x | 10.6x | 8.8x |
| EV / Op. EBITDA | 8.3x | 13.9x | 7.2x | 7.1x | 6.7x |
| P/B | 1.2x | 1.4x | 1.4x | 1.3x | 1.3x |
| FCF yield | −0.1% | −6.6% | 13.4% | 9.0% | 11.3% |
| Dividend yield | 9.2% | 6.9% | 4.6% | 4.6% | 4.6% |
| P/E at our target | 22.1x | n.m. | 14.0x | 13.2x | 11.0x |
Source: Company filings; Penmark Research model. Operating return on equity (ROE), return on net invested assets (ROA) and return on invested capital (ROIC, equivalent to after-tax return on capital employed, ROCE) use operating earnings; definitions on page 31. Multiples at $30.37 except the final row.
| Penmark vs Street | 4Q26E | FY26E | FY27E | FY28E |
|---|---|---|---|---|
| Net sales ($m) | ||||
| Penmark estimate | 10,880 | 44,033 | 43,115 | 43,977 |
| Consensus | 10,733 | 43,886 | 43,027 | n.a. |
| Prior-year period | 9,460 | 39,968 | 44,033 | 43,115 |
| Diff. vs consensus | +1.4% | +0.3% | +0.2% | n.a. |
| Growth y/y (Penmark) | +15.0% | +10.2% | −2.1% | +2.0% |
| Operating EBITDA ($m) | ||||
| Penmark estimate | 1,550 | 6,288 | 6,434 | 6,817 |
| Consensus | 1,558 | 6,296 | 5,548 | 5,731 |
| Prior-year period | 741 | 3,256 | 6,288 | 6,434 |
| Diff. vs consensus | −0.5% | −0.1% | +16.0% | +19.0% |
| Growth y/y (Penmark) | +109.2% | +93.1% | +2.3% | +6.0% |
| Operating EPS ($) | ||||
| Penmark estimate | 0.68 | 2.71 | 2.87 | 3.44 |
| Consensus | 0.56 | 2.58 | 1.84 | n.a. |
| Prior-year period | −0.34 | −0.93 | 2.71 | 2.87 |
| Diff. vs consensus | +20.7% | +5.1% | +56.0% | n.a. |
| Growth y/y (Penmark) | n.m. | n.m. | +5.9% | +20.0% |
Source: S&P Global consensus post-3Q26; Penmark Research model. 4Q26E consensus derived as FY26E mean less reported 9M26A; n.a. = not available.
Source: Company filings (A); S&P Global consensus; Penmark Research estimates (E).
Dow trades about 16% below peers on trailing EV/EBITDA and below its three-year P/B average
| Snapshot (Sep/Nov 26) | DOW | Peers | Diff. |
|---|---|---|---|
| Valuation at current prices | |||
| Trailing EV / EBITDA | 8.28x | 9.84x | −15.8% |
| Forward P/E (consensus) | 16.56x | 15.82x | +4.7% |
| Trailing EV / sales | 1.07x | 0.97x | +9.8% |
| Trailing P/B | 1.36x | 1.29x | +5.4% |
| Dividend yield | 4.6% | 3.8% | +0.8pp |
| Cycle anchor, margins and balance sheet | |||
| Through-cycle EV / EBITDA | 6.86x | 6.74x | +1.8% |
| Operating margin (9M / LTM) | 8.1% | 5.0% | +3.1pp |
| After-tax ROIC (FY27E vs LTM) | 9.4% | 6.8% | +2.6pp |
| Trailing ROE | −3.2% | 2.6% | −5.8pp |
| Net debt / EBITDA | 2.45x | 4.94x | −2.49x |
| Market value ($bn) | 22.09 | 7.48 | +195.3% |
Source: 3Q26 peer filings (LYB, WLK, EMN, CE, HUN); Yahoo Finance Nov 2026 for forward P/E, P/B, ROE and yield; Penmark Research model. Dow trailing EV/EBITDA uses full-bridge EV ($45,389m); peers and the 6.86x/6.74x cycle medians use simple EV. Dow FY27E ROIC is shown against peers’ trailing ROIC.
- Nov–Dec 26Oct (+7¢/lb) and Nov (+5¢/lb) polyethylene settlements; full hold adds +$0.86/sh vs our 1¢/lb base.
- Late Jan 274Q26 results and FY27 bridge: we model $1.55bn 4Q EBITDA vs $1.5bn guide and $1.1bn FY27 self-help.
- 1H 2027Sadara strategic review update with Saudi Aramco; exit at $1.0bn vs $1.3bn carried adds +$0.35/sh.
- Mid-2027Pending European shutdowns (Böhlen, Schkopau; Barry shut in 2Q26) toward $0.2bn run-rate uplift.
Source: Company 3Q26 earnings release and call; Penmark Research model.
- New PE capacity makes trough structural. China additions cap mid-cycle margins at 11.0% ($5.2bn EBITDA). Prob. 40%; −$16.04/sh.
- Self-help competed away in oversupply. FY27E realisation drops from 85% to 55% (−$0.4bn EBITDA) and mid-cycle retention falls to 0%. Prob. 30%; −$6.61/sh.
- Middle East de-escalation resets PE spreads. Oil-to-gas spread unwinds by 6¢/lb (−$1.2bn FY27E EBITDA). Prob. 35%; −$1.29/sh.
- Upside risk: higher T2O delivery & retention. Full FY27E delivery plus 75% mid-cycle productivity retention lift value. Prob. 45%; +$3.30/sh.
Source: Penmark Research model.
Source: Company filings, 4Q23–3Q26; spot 1.36x (−0.5 SD) at $30.37 on 18 Nov 2026. Standard deviation (SD) bands measure spread around the 1.59x mean (±2 SD = 0.63x–2.55x).
Source: Yahoo Finance global chemical snapshot (incl. uncovered BASF, SABIC, Arkema, Wacker, Sumitomo), Nov 2026; R-squared (R²) = share of P/B variance explained.
Six charts trace our Buy call from earnings to a base value of about $40
Dow’s market value tracks operating EBITDA across the cycle, and Street estimates miss the 2027 cost bridge. Retained self-help and Path2Zero lift base value $9 above the $30 share price, though discount-rate sensitivity caps conviction.
Source: Company filings and year-end market cap, FY19A–FY25A.
Source: Penmark Research model FY26E–FY27E bridge.
Source: S&P Global and Yahoo Finance broker range; Penmark Research.
Source: Company filings (A; simple EV); Penmark Research model at $30.37 (E; full-bridge EV $45,389m).
Source: Penmark Research model ($30.37 share price to $39.78 base value).
Source: Penmark Research model.
Value debates explain the $9 gap between the $30 share price and our $40 base value
Three value debates drive our $9.41 gap above the share price, while polyethylene margins explain our FY27E earnings gap versus consensus. Each debate maps to a thesis chapter and resolves across five dated checkpoints through October 2027.
| Debate | Market view | Penmark view | Independent evidence | What changes our view | Resolves |
|---|---|---|---|---|---|
| Self-help durability | Cost cuts are competed away; FY27E Street implies 17% realisation (~$220m) and zero mid-cycle credit. | 85% of FY27E guide ($1,105m) and 50% productivity held ($867m mid-cycle credit, +$8.05/sh). | FY25 savings beat $300m guide at $400m+; FY26 T2O raised from $500m to $700m; 9M26 severance $481m booked. | FY27 bridge realisation falls below 55% or SG&A/cost per ton rebounds with inflation. | Jan–Oct 27 |
| Polyethylene margin floor | Middle East normalisation and China supply cut FY27E PE margins ~8.4¢/lb ($5.5bn EBITDA). | US ethane holds reset to −4.0¢/lb (−$800m), lifting FY27E EBITDA to $6.4bn (+$886m vs Street). | US Gulf Coast crackers run above 90% vs low 80s global; US ethane near 27¢/gal; Sep +5¢/lb hike settled. | US integrated PE contracts drop >8¢/lb in 1H27 or global operating rates slip below 80%. | Dec 26–Jul 27 |
| Path2Zero optionality | At 5.9x implied EV/EBITDA, market prices Path2Zero capex drag with zero net NPV. | $1.0bn run-rate EBITDA plus $0.9bn incentives PV yields $2.7bn (+$3.70/sh) net value. | Project ~45% complete; Phase 1 end-2029, Phase 2 2030; two $650m cash incentives assumed FY31E–32E. | Remaining capex ($4.1bn) overruns >20% (~$8.3bn total) or start-up slips past 2031. | Mid 27–29 |
| Sadara & legacy claims | Bears fear $1.55bn guarantee call; headline screens omit $11.9bn non-debt claims and wait cost. | Deduct $1,258m Sadara book liability (+$0.40/sh vs call) and −$2.77/sh recovery-path drag. | 10-Q Notes 9 & 19 carry $758m negative investment + $500m guarantee; cash funding falls ~$100m/yr. | Aramco JV restructuring triggers >$1.3bn cash call, or settlement below $1.0bn adds upside. | 1H 2027 |
Source: Company 10-Q/8-K filings and 3Q26 call; S&P Global consensus; Penmark Research model.
Source: Penmark Research model (base-value bridge from $30.37 to $39.78).
How the debates map to our thesis
Three thesis chapters quantify our value bridge and FY27E earnings gap. Our value bridge adds self-help (+$8.05), Path2Zero (+$3.70), Sadara (+$0.40) and margin (+$0.04), less the −$2.77 recovery-path wait cost (present value of the after-tax profit shortfall below mid-cycle, 4Q26E to FY30E). Separately, polyethylene margins drive our +$886m FY27E EBITDA edge over consensus.
Why the market gets 2027 wrong
Consensus double-counts the margin fade while ignoring structural plant exits. Brokers extrapolate mid-2026 polyethylene weakness into FY27E ($5.5bn EBITDA) without crediting permanent fixed-cost removal at Barry (shut 2Q26), Böhlen and Schkopau or 4,500 T2O role reductions.
Source: Company calendar; industry contract schedule; Penmark Research.
After the 2025 trough, we credit about $0.9bn of Dow’s cost cuts as lasting
Dow turns cheap American natural-gas liquids into everyday food packaging, insulation foams and silicone sealants across 91 plants. Investors still price a commodity treadmill just as European plant closures and cost cuts reshape its mid-cycle earnings floor.
The scene
On the US Gulf Coast in the third quarter of 2026, Dow’s gas-fed furnaces ran above 90% capacity while the global ethylene industry ran in the low 80s. That feedstock gap let Dow lift Packaging & Specialty Plastics local prices 17% year on year and segment volume 1%, even as total Dow volume dipped 1%. Spun out of DowDuPont in April 2019, Dow supplies manufacturers across packaging, infrastructure, mobility and personal care.
What it actually does
Dow cracks ethane and propane from natural gas, alongside naphtha from crude oil, into ethylene and propylene molecules. It then links those molecules into polyethylene pellets for food wrap, polyurethane foams for home insulation, and silicone rubbers for electronics and coatings.
Why it works, and why it might not
Converters stay with Dow for multi-year food-contact qualifications and reliable Gulf Coast supply. The loop breaks if Chinese overcapacity forces Dow to hand its cost cuts back in lower resin prices, linking directly to self-help durability and the polyethylene margin floor.
How the money comes in
Product shipments generate 97% of Dow’s $40.0bn FY25A sales, billed per pound or metric ton on monthly contracts and spot orders. Packaging & Specialty Plastics contributes 50% of revenue ($20.0bn), Industrial Intermediates & Infrastructure 28% ($11.2bn), and Performance Materials & Coatings 20% ($8.1bn). Each 1¢/lb move in integrated polyethylene margin swings annual operating EBITDA by $200m; in FY26E, $1.00 of sales leaves 14.3¢ of operating EBITDA and 6.7¢ of free cash flow.
Where the story turns
After operating EBITDA peaked at $12.4bn in FY21A, Chinese plant startups and European energy costs crushed FY25A operating EBITDA to $3.3bn. Management halved the dividend to $0.35 a quarter in July 2025, shut Barry in 2Q26, slated Böhlen and Schkopau for closure, launched the $2.0bn Transform to Outperform overhaul, and named 30-year veteran Karen S. Carter chief executive officer (CEO) on 1 July 2026.
Source: FY25 Form 10-K, 3Q26 Form 8-K and call, Penmark Research model.
Packaging & Specialty Plastics is half of FY25 sales and about 70% of operating EBITDA
Source: Company Form 10-K, DEF 14A and 3Q26 release; Penmark Research model.
Source: FY25 Form 10-K segment and geographic notes; Penmark Research model for FY26E recovery panel. P&SP accounts for 70% of consolidated operating EBITDA (including Corporate) and 67% of the three-segment sum.
Feedstock integration sets Dow’s margin floor. Because Hydrocarbons & Energy crackers supply internal ethylene to Packaging & Specialty Plastics, low-cost US ethane turns oil-linked global polyethylene hikes directly into operating EBITDA.
Operating leverage works fast in both directions. With $2.8bn of annual depreciation and high fixed plant costs, a 6.1pp margin rebound from FY25A (8.1%) to FY26E (14.3%) swings free cash flow by $4.4bn (−$1.4bn to +$3.0bn).
Cash costs take 86% of sales, so small moves in resin spreads swing profits
Dow buys natural-gas liquids at North American gas-linked prices and sells plastics and intermediates at global oil-linked contract prices. Because plant staffing, maintenance and depreciation are largely fixed once crackers run, small price-over-feedstock shifts flow straight to operating EBITDA.
Source: Penmark Research model, FY26E revenue-to-operating-EBIT flow.
| Segment | FY25A Sales ($m) |
FY26E Sales ($m) |
FY26E EBITDA |
FY26E Margin |
What it sells & why customers buy | Pricing & feedstock driver |
|---|---|---|---|---|---|---|
| Packaging & Specialty Plastics (P&SP) | 19,970 | 22,882 | 4,263 | 18.6% | LLDPE/LDPE/HDPE food packaging resins ($14.6bn FY25), functional polymers, ethylene/propylene ($5.4bn). | Monthly contract indices (CDI/Argus); US ethane (~27¢/gal) vs global oil-linked naphtha ($200m per 1¢/lb). |
| Industrial Intermediates & Infra. (II&I) | 11,163 | 11,700 | 986 | 8.4% | Polyurethane systems & MDI ($7.1bn FY25) for appliance/building insulation; EO/PO alkoxylates & solvents ($4.0bn). | 40% housing-exposed; benzene, propylene and chlorine inputs; Sadara & EQUATE Middle East JVs. |
| Performance Materials & Coatings (PM&C) | 8,134 | 8,741 | 1,148 | 13.1% | Silicone elastomers & sealants ($4.9bn FY25) for electronics/personal care; architectural acrylic binders ($3.2bn). | Downstream formulation pricing sticky; upstream siloxane monomer pressured by China supply (Barry shut 2Q26). |
| Corporate | 701 | 710 | −109 | n.m. | Captive insurance, financing and unallocated enterprise services. | Directly reduced by Transform to Outperform SG&A and role cuts. |
| Consolidated Dow | 39,968 | 44,033 | 6,288 | 14.3% | 97% physical product sales across 91 sites in 29 countries. | Volume × local price/mix less hydrocarbon & energy cash cost. |
Source: FY25 Form 10-K Note 24 segment disclosures; Penmark Research model.
Pricing, billing and customer stickiness
Resin prices reset monthly, whereas downstream formulations reset quarterly or annually. In P&SP, North American converters buy on monthly negotiated contracts benchmarked to trade indices; in Consumer Solutions silicones, qualification into cosmetics, semiconductors and electric-vehicle batteries creates multi-year switching costs. Customer prepayments are negligible, with deferred revenue of just $199m at 30 September 2026.
Fixed versus variable cost leverage
Variable hydrocarbon feedstock and fuel inputs dominate cost of sales ($37.4bn in FY25A), while crackers carry steep fixed-cost thresholds. Steam crackers must run above 85% utilisation to absorb maintenance, labour and $2.8bn of annual depreciation. Shutting Barry siloxanes (completed 2Q26) and pending closures at Böhlen and Schkopau remove $0.2bn a year of structural drag by 2029.
US & Canada and EMEAI make up 71% of sales; working-capital release lifts FY26E cash conversion
Dow’s revenue equation multiplies shipped tonnage by local price and mix across US & Canada and Europe, Middle East, Africa and India (EMEAI). Highlighted driver-tree nodes mark two confirmed stock drivers, integrated polyethylene spreads and Transform to Outperform cost self-help, alongside P&SP volume. Our third confirmed driver (cash conversion and dividend cover) is detailed in Exhibit 32.
Source: Company 3Q26 release and call; Penmark Research model. Blue-shaded boxes mark confirmed stock drivers.
Source: FY25 Form 10-K geographic note (91 sites across 29 countries).
| Cash bridge | FY25A | 9M26A | FY26E | FY27E |
|---|---|---|---|---|
| Operating EBITDA | 3,256 | 4,738 | 6,288 | 6,434 |
| Cash from operations (CFO) | 1,062 | 4,287 | 5,463 | 4,618 |
| Cash conversion (%) | 32.6% | 90.5% | 86.9% | 71.8% |
| Capital expenditures | −2,479 | −1,841 | −2,501 | −2,650 |
| of which Path2Zero | n.a. | n.a. | n.a. | −1,150 |
| Free cash flow | −1,417 | 2,446 | 2,962 | 1,968 |
| Trade working capital (end) | 7,206 | 7,614 | 7,514 | 7,545 |
Source: Company 3Q26 release; Penmark Research model. n.a. = not disclosed separately prior to FY27E.
Profit-to-cash conversion and working capital
Working-capital discipline reversed FY25A’s cash burn. In FY25A, $1.2bn of working-capital outflow and restructuring dragged continuing CFO down to $1.1bn (33% conversion). Releasing over $0.4bn of working capital in 3Q26 (over $0.5bn guided for 2H26) lifted 9M26A conversion to 91%, supporting 72%–76% conversion in FY27E–FY29E even after $0.6bn of FY27E restructuring cash.
Customer, supplier and regional concentration
No single customer exceeds 10% of consolidated revenue, limiting customer concentration risk. Regional exposure is balanced across 32 North American sites, 31 EMEAI sites, 15 Asia Pacific sites and 13 Latin American sites. Key raw-material exposure sits in US Gulf Coast ethane/propane pipelines and Middle East joint-venture feedstocks: EQUATE, The Kuwait Olefins Company (TKOC) and Sadara.
Global ethylene runs in the low 80s and needs about 10% of capacity to close; US Gulf Coast crackers run above 90%
Commodity chemicals clear on the marginal producer’s cash cost. Published 2025 global polyethylene demand estimates span 118m–129m metric tons (about 43m tons exported across regions), while management estimates post-2021 builds pushed global cracker utilisation into the low 80s.
Source: FY25 Form 10-K Notes 4 & 24; 3Q26 earnings call; Penmark Research.
Source: Company filings; LyondellBasell Form 10-K; Penmark Research model.
| Cost quartile | Feedstock & region | 2026 cycle status & Dow exposure |
|---|---|---|
| 1st quartile (lowest) | Middle East ethane (Saudi Arabia, Kuwait, Qatar) | Regulated gas pricing; 2026 regional conflict curtailed output (~$160m FY26 drag at Dow’s EQUATE, TKOC and Sadara JVs). |
| 1st / low-2nd quartile | US Gulf Coast & Alberta ethane (Texas, Louisiana, Canada) | Shale NGL ethane near 5-yr average (~27¢/gal); US Gulf Coast crackers run above 90% vs global low 80s; Dow’s core profit pool. |
| 3rd quartile | Asian naphtha & coal/methanol-to-olefins (MTO/CTO) | Oil-linked naphtha and MTO/CTO plants in China and Korea set marginal Asian clearing prices; co-product credits vary. |
| 4th quartile (marginal) | European naphtha crackers (Germany, UK, France, Italy) | High energy, carbon and age penalties; 5%–6% global closures announced (~8% speculated), including Dow Böhlen & Schkopau. |
Source: Industry cost-curve studies; Dow 3Q26 call; Penmark Research.
Bottom-up demand drivers and cycle position
Packaging is resilient, whereas construction and durables remain interest-rate constrained. Industry studies expect global polyethylene demand to expand roughly 3.5%–4.4% a year on food protection, cold-chain e-commerce and emerging-market consumption. By contrast, 40% of methylene diphenyl diisocyanate (MDI) polyurethane demand depends on housing and appliances, where 5.15% 10-year US Treasury yields continue to suppress turnover.
Supply rationalisation, regulation and substitution
Management estimates closing about 10% of global ethylene capacity is required to restore mid-cycle utilisation. With 5%–6% already announced in Europe and Northeast Asia and about 8% speculated, supply discipline is underway. Regulatory plastic-waste mandates, recycled-resin targets and 2025–2026 tariff realignments pose substitution and trade-routing risks, which Dow addresses through mono-material recyclable films and its zero-Scope-1/2 Path2Zero cracker.
US ethane feedstock scale and 5% SAR&D overhead give Dow a durable cost edge over global peers
In bulk chemicals, low-quartile feedstock integration and lean overhead decide survival through troughs. Dow combines top-tier US Gulf Coast and Canadian ethane cracking with specialty silicone and elastomers franchises, while running selling, administrative and research & development (SAR&D) expense at about 5% of sales versus about 12% across chemical peers.
Source: Yahoo Finance global chemical peer snapshot (19 Nov 2026; EUR market caps converted at 1.10 USD/EUR); company filings.
Source: Company filings; 3Q26 call (SAR&D 5% vs peer 12%); Penmark assessment.
| Segment | Primary competitors | Substitutes | Customer choice criteria | Source & durability of Dow’s advantage |
|---|---|---|---|---|
| Packaging & Specialty Plastics | ExxonMobil Chemical, LyondellBasell (LYB), SABIC, Chevron Phillips, Westlake (WLK), Sinopec. | Recycled resin (rPE), paperboard, aluminium, glass, bio-polymers. | Delivered cost/lb, film dart/seal strength, run-speed on converter lines, low-carbon footprint. | Feedstock + catalyst IP: US Gulf Coast crackers above 90%, proprietary octene/ELITE metallocene resins, and Path2Zero zero-Scope-1/2 PE by 2030. |
| Industrial Intermediates & Infra. | Covestro, Wanhua Chemical, BASF, Huntsman (HUN), Shell Chemicals. | Mineral wool & fibreglass insulation; bio-based surfactants. | Regional supply reliability, formulated polyurethane system specs, purity in pharma/home care. | Mixed: Strong North American alkoxylate expansion (+$60m FY27E EBITDA), but commodity MDI trails Wanhua’s scale and carries Sadara JV drag. |
| Performance Materials & Coatings | Wacker Chemie, Shin-Etsu, Elkem, Momentive (silicones); Arkema, Celanese (CE), BASF, Eastman (coatings). | Polyurethane/acrylic sealants, epoxy thermal interface materials (TIMs), solvent-borne coatings. | OEM spec qualification, thermal/dielectric stability, regulatory & skin-safety compliance. | Downstream formulation moat: Shutting upstream Barry siloxanes (2Q26) shifts mix toward sticky electronics, EV thermal and personal-care silicones (+3% vol FY27E). |
Source: FY25 Form 10-K; Penmark Research model.
Where Dow wins: cost position and overhead
Dow averaged a 14.8% operating EBITDA margin over FY19A–FY25A, and its 8.1% FY25A trough margin stayed 490bp above LYB’s GAAP margin (3.2%). Benchmarking on the 3Q26 call showed Dow’s SAR&D ratio at about 5% of revenue against 12% for diversified peers, while Transform to Outperform removes about 4,500 roles.
Where peers press Dow: balance sheet and MDI
On a consistent trailing basis, Dow’s 2.45x net debt/EBITDA sits below the 4.94x US peer median (LYB is 1.67x), while Wanhua caps global MDI pricing. Even with manageable leverage, our equity bridge deducts $25.3bn of total claims, covering debt, minority interest, pensions, Sadara, environmental, asbestos, restructuring cash and the recovery-path drag.
New CEO Karen Carter has about 80% of pay at risk, with 30% of her bonus tied to the $2bn transformation
| Who | Tenure & background | How they are paid (FY25 Summary Compensation Table [SCT] & 2026) | What they own (at $30.37/sh) & Form 4 |
|---|---|---|---|
| Karen S. Carter Chief Executive Officer NEW CEO · JUL 2026 |
0.4 yrs as CEO (started Jul 2026); COO from Dec 2024; >30 yrs at Dow; career Dow commercial & P&SP leader. | $7.17m FY25 SCT ($6.66m ex-pension: 19% sal/other, 3% bonus, 78% equity). Jul 2026 CEO target: $1.50m salary, 165% bonus, $14.03m LTI + $4.35m promotion LTI. Bonus: 70% Op. EBIT & FCF, 30% T2O; PSUs on ROC, CFO, TSR. |
$11.49m (378,291 sh; <0.1% outst.; 7.7x CEO salary; incl. 325,683 options/units). Jul 2026 CEO grant: 24,150 RSUs + 126,640 derivative shares; zero open-market sales. |
| Jeffrey L. Tate Chief Financial Officer |
3.1 yrs as CFO (started Oct 2023); prior CFO at Leggett & Platt (2019–23) after earlier Dow finance tenure. | $6.08m FY25 SCT ($5.85m ex-pension: 20% sal/other, 3% bonus, 77% equity); FY25 base salary $0.955m, 110% bonus target. LTI: 65% PSUs (Op. ROC + Cum. CFO), 20% options, 15% RSUs. |
$2.83m direct post-Oct Form 4 (93,197 sh; <0.1%; 3.0x salary; Feb proxy 25,017 beneficial sh). 26 Oct 2026 Form 4: 25,564 sh at $33.99 code D to issuer (not market sale). |
| Jim Fitterling Executive Chair NEW ROLE · JUL 2026 |
0.4 yrs as Exec Chair (Jul 2026 to 2027 AGM); CEO 2018–Jun 2026 (~8 yrs) & Board Chair since 2020; 42 yrs at Dow. | $19.08m FY25 SCT ($17.65m ex-pension: 13% sal/other, 3% bonus, 84% equity; compensation actually paid [CAP] −$0.89m on TSR drop). Metrics: 18% FY25 bonus payout after EBIT/FCF missed threshold. |
$63.02m (2,075,141 sh; 0.29% outst.; 37.2x FY25 salary; 290,263 direct + 1,784,878 options/units). Zero open-market selling across 2025–26. |
| Amy E. Wilson General Counsel & Corp. Secretary |
7.6 yrs in role (started Apr 2019 spin-off); career Dow legal & corporate affairs executive. | $4.86m FY25 SCT ($4.37m ex-pension: 26% sal/other, 4% bonus, 70% equity); FY25 base salary $0.880m, 100% bonus target. Metrics: same 70% financial / 30% T2O bonus & PSU framework. |
$16.03m (527,945 sh; <0.1% outst.; 18.2x salary; 65,263 direct + 462,682 options/units). Small code D issuer withholding at $29.90 on 26 Feb 2026. |
Source: 2026 DEF 14A (27 Feb 2026; beneficial holdings as of 6 Feb 2026 include options exercisable and units vesting within 60 days); CEO transition Form 8-K (14 Apr 2026) and Form 8-K/A (6 Jul 2026); Form 4 filings through Nov 2026. Note: Former CTO Dr. A.N. Sreeram ($4.74m FY25 SCT; 414,046 sh) stepped down on 31 Dec 2025. Mix bar: grey = salary/other, mid-blue = cash bonus, dark-blue = equity.
Does pay reward per-share value?
Yes: trough payouts collapsed when cash flow missed, and 2026 bonuses lock onto self-help. Roughly 80% of CEO and 74% of named executive officer (NEO) target pay is at risk. In FY25A, annual bonuses paid just 18% of target after Operating EBIT and FCF missed thresholds, and CEO “compensation actually paid” (CAP) was −$0.9m. For 2026, the board set 70% of the annual bonus on Operating EBIT/FCF and 30% on Transform to Outperform (capped at 100% if financial thresholds miss), while 3-year performance share units (PSUs) run on return on capital (ROC), cash flow from operations (CFO) and total shareholder return (TSR). Ownership guidelines (6x CEO salary, 4x NEOs), clawbacks and hedging/pledging bans apply.
Board independence, voting and dilution
Governance is clean, with one-share-one-vote common stock and no controlling holder. Independent Lead Director Richard K. Davis counterbalances Jim Fitterling’s transition Chair role through the 2027 annual meeting. On 3Q26 13F filings, three institutions hold above 5%: Vanguard (12.4%), BlackRock (8.0%) and State Street (5.4%); all 22 directors and officers own 3.9m shares (0.5%). Say-on-pay won 91% support at the April 2026 annual meeting (92% in 2025), while the 2026 stock plan amendment lifted authorised plan shares from 125m to 185m.
Source: Penmark Research model, cumulative FY26E–FY28E operating cash deployment. FY26E capex ($2.5bn) includes Alberta spend; FY27E–28E Path2Zero capex ($2.4bn) is shown separately.
Management beat cost-saving targets by 33%–40%, earning partial credit while cycle calls stay discounted
Dow’s track record splits sharply between controllable costs and uncontrollable commodity spreads. Management exceeded FY25 cost savings by $100m (+33%) and raised FY26 Transform to Outperform savings from $500m to $700m (+40%), while quarterly EBITDA guidance split one beat and one miss in 2026.
Source: Company earnings releases; Penmark Research model.
How we hair-cut management guidance
We discount productivity promises by 50% at mid-cycle, not 0% or 100%. In 1Q26, Operating EBITDA of $873m beat the ~$750m guide (+16%); in 3Q26, initial ~$1,700m guidance was cut to ~$1,475m on feedstock spikes before landing at $1,553m (−9% vs initial). That record supports crediting 85% of FY27E cost cuts ($1.1bn vs $1.3bn guided) and 50% of productivity ($0.7bn) plus 100% of assumed European shutdown savings ($0.2bn).
Source: Company filings (FY24A–FY25A); Penmark Research model (FY26E–FY28E hatched). Our 2.5x gross leverage rule sits below Fitch’s 3.0x threshold.
| Capital use / action | Scale ($bn) | Return vs 7.3% WACC | Assessment & per-share impact |
|---|---|---|---|
| Path2Zero cracker | $7.5bn gross ($6.2bn net) |
Accretive (+$2.7bn NPV): lifts group ROIC to 13.5% by FY35E. | 1–2 year pause during FY25 preserved cash; ~45% built; $1.0bn run-rate EBITDA plus APIP grants of about C$1.8bn (US$1.3bn, paid post-start-up) add +$3.70/sh. |
| Maintenance & incremental capex | $1.5bn–$2.0bn per year |
Above WACC (10.7% mid-cycle ROIC): alkoxylates add +$60m FY27E. | Total capex held at $2.5bn in FY26E (below $2.7bn D&A) to protect investment-grade credit ratings. |
| Common dividend (post-50% cut) | $1.0bn/yr ($1.40/sh) |
4.6% cash yield: covered 2.9x by FY26E FCF ($3.0bn). | Cutting from $2.80 to $1.40/sh in Jul 2025 stopped debt-funded payouts ($1.5bn paid vs −$1.4bn FCF in FY25A). |
| Infrastructure & litigation cash | ~$4.2bn inflows |
Balance-sheet bridge: non-core monetisation at infrastructure yields. | Macquarie 49% Diamond Infrastructure stake (~$3.0bn proceeds; NCI $3.4bn at market) + $1.2bn Nova judgment. |
| Share buybacks vs stock-based comp. (SBC) | $0.2bn FY27E $1.1bn FY28E |
Value-accretive at $30.37: 24% discount to $39.78 base value. | Paused in FY25–26E (shares rose 705m to 726m); restarts ($230m FY27E, $1,088m FY28E) under our 2.5x gross leverage rule. |
Source: 2026 DEF 14A; 3Q26 release; Penmark Research model (7.30% capital asset pricing model [CAPM] WACC).
Dow trades on polyethylene spreads, cost cuts and dividend cover, not GAAP EPS
Four empirical tests across eight earnings prints, 105 weekly returns and 64 analyst questions isolate three confirmed stock drivers. Headline generally accepted accounting principles (GAAP) EPS rarely moves the shares on its own. Investors re-price Dow when resin spreads, cost self-help or balance-sheet cash coverage shift.
| Confirmed driver | Tests passed | Market reaction vs model value | Linked key debate | Next number to watch |
|---|---|---|---|---|
| Integrated polyethylene spreads | Four of four (events, returns, ordinary least squares [OLS], Q&A 45%) |
Stock jumped +15.9% (from $29.93) on the 3Q26 beat plus PE nominations, then fell −12.5% on 5.15% 10Y yields and weaker benzene; transient 1¢/lb is worth $0.21/sh vs structural 1pp margin worth $4.25/sh. | Polyethylene margin floor | Nov/Dec PE contract settlement (mid-Dec 2026): +5¢/lb nominated vs Penmark −4¢/lb FY27E reset. |
| Transform to Outperform cost self-help | Three of four (events, returns, Q&A 36%) |
3Q25 (+13.0%) & 3Q26 (+4.7%) jumped on cost beats, yet $30.37 prices ~0% mid-cycle retention vs our +$8.05/sh ($867m) credit. | Self-help durability | 4Q26 results & FY27 bridge (late Jan 2027 est.): Penmark $1.1bn (85% of guide) vs $1.3bn guided. |
| Cash conversion & dividend/rate safety | Four of four (events, returns, 10Y US Treasury [UST] OLS, Q&A 28%) |
2Q25 dividend cut sank stock −17.5%; 10Y UST hitting 5.15% plus weaker benzene cut stock −12.5%; +1pt WACC cuts target by −$10.91/sh to $26.93. | Path2Zero optionality | 4Q26 FCF & working capital (late Jan 2027 est.): >$500m 2H26 WC release; FY26E FCF $3.0bn. |
Source: Earnings call transcripts; Yahoo Finance price history; Penmark Research model.
Source: Yahoo Finance one-day closes on Dow’s last eight earnings releases (30 Jan 2025 to 22 Oct 2026).
Source: Yahoo Finance price return series to 18 Nov 2026.
Event-day reactions: cash and costs beat EPS
Three of the eight largest post-earnings moves exceeded ±5%, and each followed a cash, cost or resin-spread inflection. On 24 July 2025 (2Q25), halving the quarterly dividend from $0.70 to $0.35 drove a −17.5% one-day drop (−17.5pp excess vs S&P 500). Conversely, 3Q25 (+13.0%) and 3Q26 (+4.7%, +5.9pp excess) rallied on cost delivery, >$0.4bn working-capital release and +17% P&SP local pricing.
Return decomposition: earnings vs multiple
Over three and five years (−41% and −48%), collapsing EBITDA overwhelmed counter-cyclical multiple expansion. Operating EBITDA fell 41% in FY25A ($3.3bn vs $5.5bn), lifting EV/EBITDA to 13.9x at trough. Over the past 12 months (+39%), rebounding EBITDA toward $6.3bn compressed FY26E EV/EBITDA back to 7.2x as the stock rallied off its $20.93 intraday 52-week low.
Oil-to-gas spreads, 10Y yields and self-help Q&A confirm where the market misprices Dow
Source: Yahoo Finance weekly returns (Nov 2024–18 Nov 2026, n = 105); Penmark OLS.
Source: Earnings call transcripts (1Q25–3Q26, 7 Q&A calls, n = 64 turns; shares sum to 145% as turns span multiple topics); Penmark analysis.
Integrated polyethylene spreads
Claim: Oil-to-gas feedstock spreads set Dow’s weekly tape (confirmed by all four tests; 45% of Q&A; 9% OLS variance share).
Market vs model: Shares surged +15.9% (from $29.93) on the 3Q26 beat plus Oct/Nov PE nominations, then fell −12.5% as 10Y yields hit 5.15% and benzene softened. In our model, a 1-year ±4¢/lb (±$0.8bn) swing moves PV by just ±$0.86/sh (±3%), whereas a lasting ±1pp mid-cycle margin shift is worth ±$4.25/sh (±14%).
Debate & watch: Links to Polyethylene margin floor. Watch mid-Dec 2026 contract settlement (+5¢/lb nominated vs our −4¢/lb FY27E reset; ±4%–6% move).
Transform to Outperform self-help
Claim: Cost and European shutdown delivery drives earnings-day re-ratings (confirmed by three of four tests; 36% of Q&A; confident management tone).
Market vs model: 3Q25 (+13.0%) and 3Q26 (+4.7%) rewarded cost beats, yet at $30.37 the market prices ~0% retained productivity ($31.74 implied value). Our model values $0.9bn of assumed mid-cycle self-help at +$8.05/sh (+27% vs spot), leaving an ~$8/sh valuation gap.
Debate & watch: Links to Self-help durability. Watch late-Jan 2027 4Q26 release for the FY27E bridge ($1.1bn Penmark vs Street ~$220m implied; ±5%–8% move).
Cash conversion & rate/dividend safety
Claim: Free cash flow cover of the $1.40 dividend and 10Y Treasury yields govern downside beta (confirmed by all four tests; 28% Q&A; 8% OLS variance share).
Market vs model: The 2Q25 dividend cut sank DOW −17.5%, and 10Y yields hitting 5.15% plus weaker benzene knocked −12.5% off the shares in Nov 2026. Our model confirms steep rate leverage: +1pt WACC cuts our target by −$10.91/sh (−29% to $26.93, Hold) and 1.60x beta cuts it to $24.31 (Sell).
Debate & watch: Links to Path2Zero optionality. Watch late-Jan 2027 4Q26 FCF (>$0.5bn 2H26 WC release; FY26E FCF $3.0bn vs Street ~$2.3bn; ±4%–7% move).
| Candidate tested | Tests passed | Evidence from our four tests & why dropped |
|---|---|---|
| MDI & housing cycle | One of four (hedged call tone; 8% Q&A) | Housing drives 40% of MDI demand, but II&I is only 15.4% of FY26E segment EBITDA ($986m of the three-segment sum) and housing turnover added negligible explanatory power beyond 10Y Treasury yields. |
| Tariff headlines & FX | One of four (28% Q&A mentions) | Frequently asked on 1H25–1H26 calls, yet local production (91 sites in 29 countries) blunted direct margin hits and trade-policy dates failed event-study significance. |
| Standalone quarterly GAAP EPS | Zero of four | Restructuring charges ($2.6bn FY25A GAAP loss vs −$0.93 operating EPS) decouple GAAP EPS from cash generation; 1Q26–2Q26 prints moved ≤1.1% despite GAAP noise. |
Source: Earnings transcripts and company filings; Yahoo Finance; Penmark Research.
Methodological limits: Weekly OLS regression covers 105 weeks (Nov 2024–18 Nov 2026; 3-year 157-week sample yields R² = 0.34). Daily US Gulf Coast ethylene-to-ethane spreads are proxied using the WTI crude oil to Henry Hub natural gas price ratio. Q&A coding spans 64 multi-topic analyst turns across seven Q&A calls (1Q25–3Q26).
Keeping half of T2O productivity plus European closures adds about $0.9bn of mid-cycle EBITDA, or $8 a share
Source: 3Q26 release; Penmark Research model.
Source: Penmark Research model.
What the market believes vs our evidence
Consensus models FY27E EBITDA falling to $5.5bn (−$0.7bn y/y) and prices zero retained self-help at $30.37. In commodities, investors rightly suspect cost cuts leak to customers. Yet three independent sources separate Dow’s programme from generic belt-tightening:
1. Audited restructuring charges & beat cadence: Dow booked $675m of T2O severance ($481m) and implementation ($194m) charges in 9M26A. Management beat FY25 cost savings by $100m ($400m vs $300m) and raised FY26 T2O delivery from $500m to $700m on the 3Q26 call.
Physical closures, incentives & per-share value
2. Permanent plant exits: Dow shut upstream siloxanes at Barry in 2Q26 and plans to close crackers at Böhlen and chlor-alkali/vinyls at Schkopau in Germany. Those exits remove negative-margin capacity worth $0.2bn a year by 2029 without higher resin prices.
3. Incentive alignment & valuation impact: Tying 30% of 2026 executive bonuses to T2O backs execution. Crediting 50% of $1.3bn productivity ($667m) plus 100% of closures ($200m) adds $867m of mid-cycle EBITDA, worth $5.9bn of EV or +$8.05 per share before remaining restructuring cash.
| Self-help stream | Management target | Penmark credit | Value / sh | Dated signpost (confirm vs disprove) |
|---|---|---|---|---|
| T2O productivity (~4,500 roles) | ~$1,333m productivity (~2/3 of $2.0bn). | $667m mid-cycle (50% kept); $1,105m (85% of guide) in FY27E. | +$6.19/sh ($4,502m EV) |
Late Jan 2027 (4Q26 print): Confirm if FY26 T2O ≥$700m & FY27E delivery ≥$1.0bn; broken if inflation erodes >50% ($35.09/sh at 0% kept). |
| T2O commercial growth uplift | ~$667m growth (~1/3 of $2.0bn). | $0m lasting credit (0% kept at mid-cycle). | $0.00/sh (upside option) |
2Q27–3Q27 results: 75% productivity retention plus 100% FY27E delivery adds +$3.30/sh; full 100% retention adds +$4.70/sh ($44.48). |
| European asset shutdowns (Böhlen, Schkopau; Barry shut 2Q26) | $200m annualised by 2029 (starts mid-2026). | $200m mid-cycle (100% of assumed fixed-cost exit). | +$1.86/sh ($1,350m EV) |
Mid-2027 & end-2027 filings: Decommissioning milestones on schedule & remaining after-tax exit cash stays inside our $0.8bn deduction. |
Source: 3Q26 release and call; Penmark Research model (+$6.19/sh T2O and +$1.86/sh closures = +$8.05/sh gross at 6.75x; net of the present value of the after-tax profit shortfall below mid-cycle, 4Q26E to FY30E, total credit is +$4.63/sh [$39.78 vs $35.15] and 0% T2O is $35.09/sh).
US Gulf Coast crackers (>90% rate) absorb a 4¢/lb FY27E PE fade while keeping EBITDA 16% above Street
Source: Company quarterly releases and 3Q26 Form 8-K.
What the market believes vs three evidence lines
Consensus models a $0.7bn EBITDA drop in FY27E ($5.5bn vs $6.3bn) because brokers assume Middle East peace erases 2026’s PE bounce without offset. Our base case already bakes in a −4¢/lb (−$0.8bn) PE fade plus −$0.3bn MDI normalisation and still lands at $6.4bn (+$0.9bn above Street):
1. Reported P&SP operating leverage: When export logistics tightened in 2Q26, P&SP EBITDA jumped from $440m (2Q25) to $1,639m before easing to $954m in 3Q26. That remained 74% above 3Q25’s $548m, with local prices up 17% y/y, showing US Gulf Coast cost-curve torque.
2. US ethane vs global naphtha: Management reports US Gulf Coast crackers run above 90% with ethane near its 5-year average, whereas global ethylene runs in the low 80s.
3. Capacity closures & 7-yr cycle base: Announced closures reach 5%–6% of global ethylene (~8% speculated) toward management’s ~10% mid-cycle threshold, supporting Dow’s 14.8% FY19A–25A average margin over FY23–25’s 11.0% trough.
| Spread / cycle case | Operating assumption | EBITDA impact | Value / share | Dated signpost (confirm vs disprove) |
|---|---|---|---|---|
| Penmark Base Case (55% weight) | FY27E PE resets −4¢/lb; existing margins reach 16.7% by FY30E (14.8% hist. + 1.9pp T2O). | FY27E $6,434m; Norm. $7,639m |
$39.78/sh (base value) |
Mid-Dec 2026 & 1Q27 print: USGC cracker rates stay above 90% and FY27E PE contract give-back stays ≤4¢/lb. |
| Oct/Nov PE hikes stick (Catalyst upside) | Oct +7¢/lb and Nov +5¢/lb nominations settle and hold through 1H27 (+4¢/lb vs base). | FY27E +$800m (to $7,234m) |
+$0.86/sh (1-yr cash PV) |
Dec 2026 CDI/Argus settlements: Net contract increase ≥+5¢/lb holds into 1Q27 without Asian import arbitrage. |
| Further EU/Asia closures (Bull structural) | Speculated 8%–10% global ethylene closures formalised, lifting mid-cycle margin +50bp. | Norm. +$229m (to $7,868m) |
+$2.13/sh (Bull $50.92) |
1H27–Oct 2027 peer updates: Additional European/Northeast Asian cracker shutdowns lift global rates above 85%. |
| Trough margin risk vs full Bear case | New China/ME builds cap historical margin at 11.0% (credit held) vs full Bear (55% FY27E self-help, none kept at mid-cycle, −6¢/lb more PE fade). | Risk: −$1,729m norm. Full Bear: $4,552m FY27E |
−$16.04/sh risk ($16.20 full Bear) |
3Q27 operating-rate check: Global ethylene stays ≤80%, Middle East JVs restart into oversupply and PE drops ≥6¢/lb. |
Source: Dow 3Q26 call; Penmark Research model. Trough margin risk alone cuts normalised EBITDA by $1,729m (−$16.04/sh); the full Bear scenario combines lost self-help, −6¢/lb PE and Sadara to reach $4,552m FY27E EBITDA and $16.20/sh.
Path2Zero adds $2.7bn, nearly $4 a share, and FCF covers the dividend about two to three times
Source: Penmark Research model (7.3% WACC, 6.75x run-rate multiple).
Source: 3Q26 and 4Q25 calls; Penmark Research model.
What the market believes vs sunk-capex reality
Near-term consensus multiples penalise Dow for $4.1bn of remaining FY27E–FY30E Path2Zero construction capex while crediting zero FY30E–FY32E EBITDA. Three facts refute treating Path2Zero as a zero-NPV cash sink:
1. About 45% of capital is already sunk: Of the $7.5bn gross project budget, roughly $3.4bn has been spent through late 2026. Remaining construction capex ($1.15bn in FY27E, $1.2bn each in FY28E and FY29E, and $0.58bn in FY30E) has a present value of −$3.6bn.
2. APIP grants reduce net cost to $6.2bn: Alberta Petrochemicals Incentive Program (APIP) grants of about C$1.8bn (US$1.3bn) cut net project cost from $7.5bn to $6.2bn. We assume two $650m payments after start-up in FY31E–FY32E (+$0.9bn PV); federal credits are not modelled.
Cash conversion, Sadara & dated signposts
3. Cash conversion funds both capex and the $1.0bn dividend: Continuing CFO surged from $1.1bn in FY25A to $4.3bn in 9M26A (91% conversion, 84% trailing twelve months), leaving $2.4bn of 9M26A FCF after $1.8bn of capex. From FY26E to FY29E, FCF ($3.0bn, $2.0bn, $2.4bn, $2.7bn) covers common dividends 2.9x, 1.9x, 2.4x and 2.5x.
Value & Sadara link: Capitalising $1.0bn of FY32E Path2Zero EBITDA at 6.75x ($4.7bn PV) plus +$0.7bn FY30E–31E ramp PV yields +$2.7bn (+$3.70/sh); ±$200m on run-rate EBITDA moves value by ±$1.48/sh. Exiting Sadara below our $1.3bn deduction ($758m negative investment + $500m guarantee) adds +$0.35/sh upside vs −$0.40/sh if called.
Margins ranged from 8% to 23% over seven years; restructuring charges opened a wide GAAP gap
| Line item | FY19A | FY20A | FY21A | FY22A | FY23A | FY24A | FY25A | 9M26A |
|---|---|---|---|---|---|---|---|---|
| Net sales | 42,951 | 38,542 | 54,968 | 56,902 | 44,622 | 42,964 | 39,968 | 33,153 |
| Net sales growth, y/y | n.a. | −10.3% | +42.6% | +3.5% | −21.6% | −3.7% | −7.0% | +8.7% |
| Operating EBITDA | 7,290 | 5,589 | 12,375 | 9,348 | 5,389 | 5,482 | 3,256 | 4,738 |
| Operating EBITDA margin | 17.0% | 14.5% | 22.5% | 16.4% | 12.1% | 12.8% | 8.1% | 14.3% |
| Operating EBIT | 4,352 | 2,715 | 9,533 | 6,590 | 2,778 | 2,588 | 422 | 2,689 |
| GAAP net income to Dow Inc. | −1,359 | 1,225 | 6,311 | 4,582 | 589 | 1,116 | −2,623 | 646 |
| GAAP diluted EPS ($/sh) | −1.84 | 1.64 | 8.38 | 6.28 | 0.82 | 1.57 | −3.70 | n.a. |
| Operating diluted EPS ($/sh) | n.a. | n.a. | n.a. | n.a. | 2.24 | 1.71 | −0.93 | 2.04 |
| Capital expenditures | n.a. | 1,252 | 1,501 | 1,823 | 2,356 | 2,940 | 2,479 | 1,841 |
| Operating ROIC after tax | 12.1% | 8.5% | 24.4% | 15.7% | 6.9% | 6.3% | 1.0% | n.a. |
Source: FY19–FY25 Form 10-K filings and 3Q26 release; Penmark Research model. n.a. = not available in model series. 9M26A operating EPS of $2.04 uses the nine-month diluted share count; reported quarters sum to $2.02.
Source: Company filings (FY25A); Penmark Research model (FY26E–29E).
| Item | Reported scale | Quality check & model treatment |
|---|---|---|
| GAAP “significant items” | −$1,961m FY25A; −$829m 9M26A | GAAP restructuring & EU asset write-downs excluded from operating earnings widened the GAAP gap ($646m vs $1,475m in 9M26A); we deduct $0.8bn remaining after-tax restructuring cash in our EV bridge. |
| Sadara JV exposure | $758m neg. inv. +$500m guar. | Carried in noncurrent obligations and fair-value guarantees (Notes 9 & 19); we deduct the full $1,258m in our equity bridge. |
| Pension & OPEB deficit | $4,318m pre-tax ($3,239m net) | Down from $4,694m at Dec-25; deducted after tax in full ($3.2bn) rather than ignored in EBITDA multiples. |
| Environmental & asbestos | $991m + $564m ($1,166m net) | 10-Q Note 12 flags environmental costs up to ~2.5x accrued as reasonably possible; after-tax accruals ($1.2bn) deducted in EV bridge. |
| Deferred rev. & leases | $199m def. rev.; $1,369m leases | Minimal prepayments ($199m vs $221m Dec-25); operating leases included on GAAP balance sheet. |
Source: 3Q26 Form 10-Q Notes 9, 12 & 19; Penmark Research model.
Operating EBITDA climbs from $6.3bn in FY26E to $8.0bn in FY30E as self-help and Path2Zero arrive
Source: Penmark Research model (FY27E operating bridge).
| Operating forecast | FY25A | 9M26A | 4Q26E | FY26E | FY27E | FY28E | FY30E | FY35E |
|---|---|---|---|---|---|---|---|---|
| P&SP net sales | 19,970 | 17,082 | 5,800 | 22,882 | 21,939 | 22,378 | 23,282 | 25,705 |
| II&I net sales | 11,163 | 8,850 | 2,850 | 11,700 | 11,462 | 11,692 | 12,164 | 13,430 |
| PM&C & Corporate net sales | 8,835 | 7,221 | 2,230 | 9,451 | 9,713 | 9,907 | 10,308 | 11,381 |
| Alberta Path2Zero net sales | 0 | 0 | 0 | 0 | 0 | 0 | 960 | 2,400 |
| Consolidated net sales | 39,968 | 33,153 | 10,880 | 44,033 | 43,115 | 43,977 | 46,714 | 52,916 |
| Net sales growth, y/y | −7.0% | +8.7% | +15.0% | +10.2% | −2.1% | +2.0% | +4.1% | +1.9% |
| Existing-assets Operating EBITDA | 3,256 | 4,738 | 1,550 | 6,288 | 6,434 | 6,817 | 7,624 | 8,417 |
| Alberta Path2Zero EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | 400 | 1,000 |
| Consolidated Operating EBITDA | 3,256 | 4,738 | 1,550 | 6,288 | 6,434 | 6,817 | 8,024 | 9,417 |
| Operating EBITDA margin | 8.1% | 14.3% | 14.2% | 14.3% | 14.9% | 15.5% | 17.2% | 17.8% |
| Depreciation & amortisation | 2,834 | 2,049 | 670 | 2,719 | 2,726 | 2,717 | 2,730 | 3,055 |
| Operating EBIT | 422 | 2,689 | 880 | 3,569 | 3,707 | 4,100 | 5,293 | 6,362 |
| Operating net income to Dow | −662 | 1,475 | 492 | 1,967 | 2,072 | 2,399 | 3,267 | 4,013 |
| Operating diluted EPS ($/sh) | −0.93 | 2.04 | 0.68 | 2.71 | 2.87 | 3.44 | 5.21 | 7.77 |
Source: Company filings (FY25A, 9M26A); Penmark Research model (ten-year long-cycle forecast to FY35E). 9M26A operating EPS of $2.04 uses the nine-month diluted share count; reported quarters sum to $2.02.
Revenue path: FY27E reset, then +2% + Path2Zero
Because chemical cycles span seven to ten years, we model ten explicit forecast years through FY35E. After FY26E’s +10% price-led rebound ($44.0bn, including $10.9bn in 4Q26E), FY27E sales dip −2% to $43.1bn as −4¢/lb PE and MDI resets outweigh +2% P&SP and +3% downstream silicones volume growth. Existing assets then grow +2%/yr while Path2Zero adds $1.0bn in FY30E, $2.0bn in FY31E and $2.4bn at full run-rate in FY32E.
Fixed/variable cost path & operating leverage
Existing-asset EBITDA margins step linearly from 14.9% in FY27E to 16.7% at FY30E mid-cycle. Variable NGL/naphtha spreads normalise gradually while fixed-cost removal ($1.1bn in FY27E, 85% of guide, plus European shutdowns completing by 2029) lifts margins; D&A holds flat near $2.7bn through FY30E because capex stays at or below D&A. Adding high-margin Path2Zero ethane tons (42% EBITDA margin) lifts consolidated margin to 17.2% in FY30E and 17.8% in FY35E.
In line with the Street for FY26E, then 16% above on FY27E EBITDA and 56% above on EPS
| Period & metric | Penmark | Consensus / Guide | Gap | Analytical reason for gap |
|---|---|---|---|---|
| 4Q26E Op. EBITDA ($m) | 1,550 | ~1,500 guide | +3.3% | Partial Oct PE +7¢/lb carry-over offsets normal 4Q packaging seasonality ($6.2bn FY guide). |
| FY26E Net sales ($m) | 44,033 | 43,886 Street | +0.3% | 9M26A $33.2bn actuals leave only $10.9bn in 4Q26E; top line is essentially locked. |
| FY26E Op. EBITDA ($m) | 6,288 | 6,296 Street | −0.1% | In line with Street mean ($6.3bn) and +0.8% above management’s implied $6.2bn guide. |
| FY26E Op. EPS ($/sh) | 2.71 | 2.58 Street | +5.1% | Street’s implied 4Q26E EPS ($0.56: FY $2.58 less 9M $2.02) looks low for ~$1.55bn of EBITDA; brokers’ below-the-line assumptions are not visible. |
| FY27E Net sales ($m) | 43,115 | 43,027 Street | +0.2% | Both Penmark (−2.1%) and Street (−2.0%) model 2026 resin pricing easing in FY27E. |
| FY27E Op. EBITDA ($m) | 6,434 | 5,548 Street | +16.0% | Core gap (+$886m): Street models −$748m fade with minimal T2O offset; we pair +$1,105m T2O (85% of guide) against −$800m PE & −$300m MDI. |
| FY27E Op. EPS ($/sh) | 2.87 | 1.84 Street | +56.0% | Fixed D&A ($2.7bn) and net interest ($0.7bn) magnify the +$886m EBITDA gap at the bottom line. |
| FY28E Op. EBITDA ($m) | 6,817 | 5,731 Street | +19.0% | Continued EU shutdown savings and +60bp margin step toward 16.7% mid-cycle (+$1.1bn vs Street). |
Source: S&P Global consensus; company guidance; Penmark Research model.
| Cash & balance-sheet bridge | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E |
|---|---|---|---|---|---|---|
| Cash from operations (CFO) | 1,062 | 5,463 | 4,618 | 5,148 | 5,470 | 5,972 |
| Capital expenditures, total | −2,479 | −2,501 | −2,650 | −2,750 | −2,800 | −2,575 |
| of which Path2Zero | n.a. | n.a. | −1,150 | −1,200 | −1,200 | −575 |
| Free cash flow (FCF) | −1,417 | 2,962 | 1,968 | 2,398 | 2,670 | 3,397 |
| Common & NCI dividends | −1,490 | −1,315 | −1,316 | −1,310 | −1,379 | −1,506 |
| Debt repaid / (drawn) | n.a. | 748 | 1,255 | 0 | 0 | 0 |
| Share buybacks (at rolled base value) | 0 | 0 | −230 | −1,088 | −1,290 | −1,891 |
| Ending net debt ($m) / Net debt/EBITDA | 14,345 (4.41x) | 13,206 (2.10x) | 12,784 (1.99x) | 12,784 (1.88x) | 12,784 (1.77x) | 12,784 (1.59x) |
Source: FY25 Form 10-K; Penmark Research model (minimum cash floor $3.3bn from FY27E; gross debt $16.1bn under our 2.5x gross leverage rule, below Fitch’s 3.0x trigger; n.a. = not available separately).
| Driver shock | EBITDA | Op. EPS | FCF |
|---|---|---|---|
| Base case FY27E | $6,434m | $2.87 | $1,968m |
| PE margin ±1¢/lb | ±$200m | ±$0.22 | ±$156m |
| PE margin ±4¢/lb (no fade / 2x fade) | ±$800m | ±$0.86 | ±$624m |
| T2O FY27E at 100% vs 55% (vs 85%) | +$195m / −$390m | +$0.21 / −$0.42 | +$152m / −$304m |
| MDI & housing ±$200m | ±$200m | ±$0.22 | ±$156m |
Source: Penmark Research model (22% operating tax rate).
Balance-sheet rules in our model
Deleveraging comes before buybacks. Excess cash repays $0.7bn of debt in FY26E and $1.3bn in FY27E until gross debt reaches $16.1bn under our 2.5x gross leverage rule with $3.3bn of minimum cash. Only above that threshold does surplus cash retire shares, priced conservatively at the higher of share price and rolled base value ($40.95/sh in FY27E rising to $47.10/sh in FY30E) so buybacks never artificially inflate per-share value. Spot net debt at 30 Sep 2026 is $13.4bn ($17.5bn debt less $4.1bn cash).
At 6.75x mid-cycle EBITDA plus Path2Zero, less $25bn of claims, base value is about $40 a share
Commodity chemical margins mean-revert, so we value Dow on mid-cycle EV / Operating EBITDA (6.75x) rather than trough or spike earnings. We reject standalone P/E (EPS swung from −$3.70 to $2.71E), sum-of-the-parts (shared ethylene crackers) and FY27E multiples (below mid-cycle operating rates).
Source: Penmark Research model at 18 Nov 2026 (727.4m diluted shares).
| Valuation build (18 Nov 2026) | Value | Per sh |
|---|---|---|
| Trend revenue (FY19A–25A avg) | 45,845 | $63.03 |
| Historical mid-cycle margin (14.8%) | 6,772 | $9.31 |
| Assumed self-help credit (50% T2O + EU) | 867 | $1.19 |
| Normalised Op. EBITDA (16.7%) | 7,639 | $10.50 |
| EV, existing assets at 6.75x | 51,563 | $70.89 |
| Path2Zero project NPV | 2,693 | $3.70 |
| Total enterprise value | 54,255 | $74.59 |
| Less: Net debt ($17,539m − $4,142m) | −13,397 | −$18.42 |
| Less: NCI at market ($2,943m InfraCo+book) | −3,439 | −$4.73 |
| Less: Pension/OPEB ($3,239m) & Sadara ($1,258m) | −4,497 | −$6.18 |
| Less: Env./asbestos ($1,166m) & restruct. ($800m) | −1,966 | −$2.70 |
| Less: Recovery-path shortfall PV (to FY30E) | −2,018 | −$2.77 |
| Primary base equity value (727.4m sh) | 28,939 | $39.78 |
| Memo: Value at 14.8% hist. margin (no credit) | 25,570 | $35.15 |
Source: Penmark Research model.
| Company | EV ($m) | EV/EBITDA | EV/Sales | Op. mgn | ND/EB |
|---|---|---|---|---|---|
| LyondellBasell (LYB) | 25,581 | 6.08x | 0.80x | 12.6% | 1.67x |
| Westlake (WLK) | 11,071 | 15.36x | 0.97x | 1.4% | 4.29x |
| Eastman (EMN) | 11,925 | n.a. | 1.32x | n.a. | n.a. |
| Celanese (CE) | 15,075 | 9.24x | 1.53x | 7.7% | 6.24x |
| Huntsman (HUN) | 3,139 | 10.43x | 0.51x | 2.3% | 5.59x |
| Peer median (30 Sep 26) | 11,925 | 9.84x | 0.97x | 5.0% | 4.94x |
| Dow at $30.37 (LTM) | 45,389 | 8.28x | 1.07x | 8.1% | 2.45x |
| LYB 13y / Dow FY19–25 | n.a. | 6.74x / 6.86x | n.a. | 14.8% | n.a. |
Source: Peer 3Q26 filings; GuruFocus; Penmark Research model. Dow LTM EV uses $45,389m full-bridge EV; peers and cycle medians use simple EV.
Weighted value of $36 rolls to our $38 target (+29%), but two discount-rate tests flip the call
Source: Penmark Research model (probability weights reflect analyst judgement).
Source: Penmark Research model (bars show base value vs $39.78; rolled targets flip at $26.93 Hold and $24.31 Sell).
| Scenario & driver link (full model re-run) | Bear (25%) | Base (55%) | Bull (20%) | Prob.-wtd |
|---|---|---|---|---|
| FY27E PE margin vs FY26E / Self-help realisation | −10¢/lb / 55% | −4¢/lb / 85% | 0¢/lb / 100% | n.a. |
| T2O productivity retained / Through-cycle margin | 0% / 11.0% (FY23–25) | 50% / 14.8% (FY19–25) | 100% / 14.8% + growth | n.a. |
| Path2Zero run-rate EBITDA / Sadara deduction | $700m / $1,550m | $1,000m / $1,258m | $1,100m / $1,000m | n.a. |
| FY27E Op. EBITDA ($m) / Operating EPS ($/sh) | $4,552m / $0.83 | $6,434m / $2.87 | $7,674m / $4.43 | n.a. |
| Normalised existing-asset Op. EBITDA ($m) | $5,240m | $7,639m | $8,639m | $7,239m |
| Primary value per share at price date (18 Nov 2026) | $16.20 (−46.7%) | $39.78 (+31.0%) | $50.92 (+67.7%) | $36.11 (+18.9%) |
| Rolled 12-month price target (at Ke 9.38% − yield 4.61%) | $16.97 (−44.1%) | $41.68 (+37.3%) | $53.35 (+75.7%) | $37.84 (+24.6%) |
| 12-month total return incl. $1.40 dividend / Implied rating | −39.5% (Sell) | +41.9% (Buy) | +80.3% (Buy) | +29.2% (Buy) |
| Cross-check full-cycle DCF value per share | $13.73 | $54.73 | $75.50 | $48.64 |
Source: Penmark Research model.
Source: Penmark Research model (includes +1.9pp assumed self-help credit).
Reconciliation to Page 1 target & Low conviction
Weighting Bear ($16.20 × 25%), Base ($39.78 × 55%) and Bull ($50.92 × 20%) gives $36.11/sh today. Rolling $36.11 forward 12 months at cost of equity (9.4%) less dividend yield (4.6%) yields our $37.84 Page 1 target (+24.6% price upside, +29.2% rated total return).
The DCF gives about $55 a share because it uses a lower discount rate than our 6.75x multiple implies
Definitions in plain English: Weighted average cost of capital (WACC, 7.3%) is the blended annual return debt and equity investors require to fund Dow’s assets. Terminal growth (2.0%) is the steady annual cash-flow growth assumed after our ten-year forecast ends in FY35E. A reverse discounted cash flow (reverse DCF) solves backwards from today’s $30.37 share price to find what discount rate or margin the market is implicitly pricing in.
Source: Penmark Research model.
| Reconciliation & reverse-DCF solve | Value | vs Primary |
|---|---|---|
| Primary EV (after $2,018m recovery path) | $52,237m | n.a. |
| Full-cycle DCF EV (7.30% CAPM WACC) | $61,837m | +18.4% |
| DCF equity value /sh (rolled 1.0121x) | $54.73/sh | +37.6% |
| DCF with terminal at 6.75x FY35E EBITDA | $47.01/sh | +18.2% |
| DCF at zero terminal growth (g = 0%) | $50.18/sh | +26.1% |
| DCF at return on new invested capital (RONIC) = WACC (7.3%) | $51.16/sh | +28.6% |
| DCF at 8.19% rate embedded in 6.75x | $42.46/sh | +6.7% |
| Reverse DCF: Price-implied ERP / WACC | 7.89% / 9.44% | =$30.37 |
| Reverse multiple: Price-implied EV/norm. EB | 5.85x | =$30.37 |
| Reverse margin: Price-implied mid-cycle mgn | 14.45% | =$30.37 |
Source: Penmark Research model.
| DCF cash-flow build | 4Q26E | FY27E | FY28E | FY29E | FY30E | FY31E | FY32E | FY33E | FY34E | FY35E |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating EBIT | 880 | 3,707 | 4,100 | 4,493 | 5,293 | 5,914 | 6,176 | 6,286 | 6,323 | 6,362 |
| Tax on EBIT (22.0%) | −194 | −816 | −902 | −988 | −1,165 | −1,301 | −1,359 | −1,383 | −1,391 | −1,400 |
| Depreciation & amortisation | 670 | 2,726 | 2,717 | 2,721 | 2,730 | 2,712 | 2,756 | 2,804 | 2,929 | 3,055 |
| Capital expenditures | −660 | −2,650 | −2,750 | −2,800 | −2,575 | −3,737 | −3,826 | −3,894 | −4,025 | −4,158 |
| APIP grants, WC & restruct. cash | −56 | −480 | −268 | −232 | −325 | 301 | 424 | −167 | −170 | −173 |
| Unlevered free cash flow (UFCF) | 640 | 2,488 | 2,897 | 3,194 | 3,959 | 3,889 | 4,171 | 3,647 | 3,666 | 3,686 |
| Present value at 7.30% WACC | 635 | 2,360 | 2,561 | 2,631 | 3,039 | 2,782 | 2,781 | 2,266 | 2,123 | 1,989 |
Source: Penmark Research model (PV of explicit UFCF = $23.2bn; PV of terminal value = $38.7bn, 63% of $61.8bn DCF EV; claims = $22.5bn).
Fourth-quarter results and the FY27 self-help bridge in late January are the first big test
Source: Penmark Research model (unweighted $/sh; upside catalysts sum to ~$6.70/sh).
Next numbers to watch by confirmed stock driver
Integrated PE spreads: Nov/Dec 2026 CDI US contract settlements (+7¢/lb Oct and +5¢/lb Nov nominated; we take +1¢/lb in 4Q26E vs ~0¢ in guide; full settlement adds +$0.8bn FY27E EBITDA or +$0.86/sh).
Transform to Outperform self-help: Late Jan 2027 (est.) 4Q26 call FY27 bridge (Penmark $1.1bn, 85% of $1.3bn guide, vs ~$220m implied in Street $5.5bn EBITDA; 100% FY27E delivery adds +$195m EBITDA, while 75% mid-cycle retention adds +$3.30/sh).
Cash conversion & rate safety: 4Q26 CFO ($1.2bnE, $0.5bn 2H26 WC release) and Mar 2027 completion of ~$1.4bn debt retirement.
| Timing | Event & driver | Penmark expectation | Street / market view | Stock & rating impact |
|---|---|---|---|---|
| Nov–Dec 2026 | Oct (+7¢/lb) & Nov (+5¢/lb) US PE contract settlements | ~1¢/lb sticks in 4Q26E; −4¢/lb fade in FY27E | Assumes hikes fail and FY27E resets −8.4¢/lb | +$0.86/sh if hikes stick across FY27E (35% prob.) |
| Late Jan 2027 (est.) | 4Q26 results & formal FY27 T2O self-help bridge | 4Q26E EBITDA $1,550m ($0.68 EPS); $1,105m (85% of guide) | ~$1,500m guide ($0.56 Street EPS); ~$5.5bn FY27E EBITDA | Primary re-rating event as FY27E Street revises up |
| Mar 2027 | ~$1.4bn debt retirement milestone & 1Q27 PE check | Gross debt steps toward $16.1bn (our 2.5x gross leverage rule) | Sceptical on FCF cover of $1.40/sh dividend | Narrows equity credit risk premium |
| 1H 2027 | Sadara JV strategic review & Aramco talks | Settled near $1,258m recorded obligation | Fears full guarantee call ($1,550m bear case) | +$0.35/sh if settled ~$258m below book (35% prob.) |
| Mid-2027 | EU cracker closures & peer shutdowns (Barry shut 2Q26) | Böhlen/Schkopau progress; global closures >6% | Treats FY23–25 overbuild as permanent | +$2.13/sh if extra closures add +0.5pp margin (40%) |
| Late 2027–1H28 | Path2Zero ~65%+ build & potential partner deal | On budget ($7.5bn gross; $1.0bn run-rate EBITDA) | Zero NPV credit until 2029–30 start-up | Crystallises $2.7bn ($3.70/sh) project NPV |
Source: 3Q26 release and earnings call; Penmark Research model (4Q26 date estimated from prior late-Jan releases).
| Indicator | Thesis confirmed if | Thesis broken if (triggers downgrade review) |
|---|---|---|
| Integrated USGC PE margin | FY27E give-back stays within −4¢/lb of FY26E; USGC crackers run >90% | Middle East/China surge resets PE ≥8–10¢/lb lower; P&SP EBITDA <$3.2bn |
| T2O productivity retention | Cost savings hit ≥$275m/qtr in FY27 (≥85% of $1.3bn target) | Wage inflation & discounting erode >45% of savings; FY27E EBITDA <$5.2bn |
| Cash conversion & dividend | CFO / Op. EBITDA stays 70%–80% and FY27E FCF ≥$1.8bn (>$1.3bn div.) | Cash conversion drops <60% or working capital absorbs >$500m, forcing borrowing |
| Discount rate & chemical beta | 10Y UST stays ≤5.15% and levered beta near 1.02x (WACC ~7.3%) | WACC +1pt (8.3%) cuts target to $26.93 (Hold); 1.60x beta cuts to $24.31 (Sell) |
Source: Penmark Research model.
A permanent China overbuild (−$16) and lost self-help (−$7) drive our $16 bear case
Source: Penmark Research model (unweighted $/sh).
What would end our thesis ($16.20/sh bear case)
Our Buy thesis breaks if Chinese ethylene self-sufficiency and stalled European closures lock global operating rates in the low 80s permanently. Because $25.3bn of debt, minority, pension and legacy claims sit ahead of common equity, cutting historical through-cycle margin from 14.8% to 11.0% with the self-help credit unchanged (−$1.7bn normalised EBITDA) wipes out $16.04/sh of equity value, pulling full-model Bear value down to $16.20/sh (−47%).
| Risk factor | Prob. | Model shock | Value /sh | Mechanism, filing evidence & mitigation |
|---|---|---|---|---|
| FY23–25 overbuild becomes new mid-cycle | 40% | −$1,729m norm. EBITDA | −$16.04 | New Chinese crackers & restarted JVs prevent 10% capacity exit; historical margin reverts to 11.0% (vs 14.8% history), credit held. |
| T2O self-help competed away | 30% | −$390m FY27E; 0% mid-cycle | −$6.61 | 2023 & 2025 $1bn cost programmes coincided with falling margins; FY27E realisation drops from 85% to 55% and mid-cycle retention falls to 0%. |
| Middle East de-escalation resets PE | 35% | −$1,200m FY27E (−10¢/lb) | −$1.29 | Unwinding 2026 shipping/oil disruption compresses oil-to-gas spread; cuts near-term FCF, though mid-cycle multiple buffers EV. |
| Higher-for-longer rates & housing | 40% | −$200m FY27E MDI | −$0.21 | 5.15%+ 10Y US Treasury yields suppress housing turnover and appliances (40% of MDI demand). |
| Discount-rate / WACC shock (+1pt) | Sens. | WACC 7.3% → 8.3% | −$10.91 target | Lifting WACC +100bp cuts our rolled 12-month target from $37.84 to $26.93 (−6.7% total return, Hold). |
| Sadara debt guarantee called | 20% | +$292m EV bridge claim | −$0.40 | Creditors call Dow’s share of project guarantees plus interest ($1,550m bear vs $1,258m recorded in 3Q26 10-Q). |
| Environmental & asbestos escalation | Med. | Up to ~2.5x $991m accrual | Up to ~−$1.53 | 3Q26 10-Q Note 12 flags environmental remediation up to ~2.5x accrued as reasonably possible (~$1.1bn after-tax unmodelled). |
| Path2Zero capex / carbon-policy ESG | Med. | $4.1bn capex / $0.9bn APIP | Up to −$2.22 | Bear case ($700m run-rate EBITDA vs $1.0bn) cuts Path2Zero NPV from $2.7bn to $1.1bn (−$1.6bn) if build overruns >20% (~$8.3bn) or credits weaken. |
| CEO transition & 4,500-role cuts | Low–Med. | Operational / reliability | Qualitative | Karen S. Carter became CEO on 1 Jul 2026 while cutting 4,500 roles (~70% done); cracker outages or safety incidents hurt volume. |
Source: FY25 Form 10-K Item 1A and 3Q26 Form 10-Q Notes 9, 12 & 19; Penmark Research model.
Institutions hold 76% of shares, short interest fell 27% since August, and 75% of the Street rates Hold or Sell
Source: Exchange bi-weekly short-interest settlements (May–Oct 2026).
Source: S&P Global (20 analysts, Oct 2026); Penmark Research.
Trading liquidity, index status & Street split
Liquidity & indexes: Dow trades 8.56m shares/day ($260.9m 3M average daily trading value [ADTV], Yahoo Finance) with 99.5% public float (723.9m basic shares; zero lock-ups; 68.1m treasury shares) and sits in the S&P 500 and Materials Select Sector (XLB) indexes.
Street skew: Across the 20 analysts in the October 2026 S&P Global set, only 5 rate Buy vs 13 Hold and 2 Sell (mean target $33.29; median $32.00; range $29–$41; 3-month revision trend down).
| Reported 13F institution | 3Q26 shares | % of basic sh | 3Q26 value ($m) | Reported q/q sh change | Reported q/q % |
|---|---|---|---|---|---|
| The Vanguard Group | 90,113,893 | 12.45% | 2,481.7 | +565,074 | +0.63% |
| BlackRock, Inc. | 57,873,851 | 8.00% | 1,593.8 | −3,868,729 | −6.27% |
| State Street Corp. | 38,787,417 | 5.36% | 1,068.2 | +918,007 | +2.42% |
| AQR Capital Management | 29,504,632 | 4.08% | 812.0 | +13,806,393 | +87.95% |
| Geode Capital Management | 20,086,061 | 2.77% | 553.2 | +804,694 | +4.17% |
| Capital World Investors | 20,039,052 | 2.77% | 551.9 | +4,294,552 | +27.28% |
| Two Sigma Investments | 19,243,262 | 2.66% | 530.0 | +1,369,896 | +7.66% |
| Morgan Stanley | 14,232,067 | 1.97% | 392.0 | −867,699 | −5.75% |
| Pzena Investment Management | 11,904,775 | 1.64% | 327.9 | −602,236 | −4.82% |
| Invesco Ltd. | 11,599,901 | 1.60% | 319.5 | +1,930,697 | +19.97% |
| Total 13F filers (1,159 institutions) | 549,300,424 | 75.88% | 15,127.7 | −12,117,051 | −2.16% |
Source: Form 13F filings for quarters ended 30 Jun 2026 and 30 Sep 2026 (723.882m shares outstanding at 30 Sep 2026; values at $27.54 quarter-end close).
The model reaches $8.0bn of EBITDA in FY30E and $9.4bn in FY35E
| Income statement | FY24A | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E | FY35E |
|---|---|---|---|---|---|---|---|---|
| Existing-assets net sales | 42,964 | 39,968 | 44,033 | 43,115 | 43,977 | 44,857 | 45,754 | 50,516 |
| Alberta Path2Zero net sales | 0 | 0 | 0 | 0 | 0 | 0 | 960 | 2,400 |
| Consolidated net sales | 42,964 | 39,968 | 44,033 | 43,115 | 43,977 | 44,857 | 46,714 | 52,916 |
| Existing-assets Op. EBITDA | 5,482 | 3,256 | 6,288 | 6,434 | 6,817 | 7,214 | 7,624 | 8,417 |
| Alberta Path2Zero Op. EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | 400 | 1,000 |
| Consolidated Operating EBITDA | 5,482 | 3,256 | 6,288 | 6,434 | 6,817 | 7,214 | 8,024 | 9,417 |
| Depreciation & amortisation | −2,894 | −2,834 | −2,719 | −2,726 | −2,717 | −2,721 | −2,730 | −3,055 |
| Operating EBIT | 2,588 | 422 | 3,569 | 3,707 | 4,100 | 4,493 | 5,293 | 6,362 |
| Net interest (income less expense) | −611 | −713 | −670 | −667 | −640 | −672 | −720 | −833 |
| Operating tax (22% E) & NCI | −771 | −371 | −932 | −969 | −1,061 | −1,141 | −1,306 | −1,516 |
| Operating net income to Dow | 1,206 | −662 | 1,967 | 2,072 | 2,399 | 2,680 | 3,267 | 4,013 |
| GAAP / post-restructuring net income | 1,116 | −2,623 | 982 | 1,623 | 2,282 | 2,602 | 3,267 | 4,013 |
Source: FY24–FY25 Form 10-K; Penmark Research model (FY31E–34E omitted for width; full 10y DCF in Exhibit 74).
| Cash flow & balance sheet | FY24A | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E | FY35E |
|---|---|---|---|---|---|---|---|---|
| Cash from operations (continuing) | 2,914 | 1,062 | 5,463 | 4,618 | 5,148 | 5,470 | 5,972 | 7,194 |
| Capital expenditures (incl. Alberta) | −2,940 | −2,479 | −2,501 | −2,650 | −2,750 | −2,800 | −2,575 | −4,158 |
| Free cash flow (FCF) | −26 | −1,417 | 2,962 | 1,968 | 2,398 | 2,670 | 3,397 | 3,036 |
| Dividends to Dow & NCI | −1,966 | −1,490 | −1,315 | −1,316 | −1,310 | −1,379 | −1,506 | −2,092 |
| Share buybacks | −494 | 0 | 0 | −230 | −1,088 | −1,290 | −1,891 | −945 |
| Cash & equivalents | 2,189 | 3,816 | 4,133 | 3,300 | 3,300 | 3,300 | 3,300 | 3,300 |
| Trade working capital | 6,453 | 7,206 | 7,514 | 7,545 | 7,696 | 7,850 | 8,175 | 9,260 |
| Net property (PP&E) | 22,004 | 22,250 | 22,428 | 22,499 | 22,661 | 22,855 | 22,802 | 27,244 |
| Gross debt | 16,343 | 18,161 | 17,339 | 16,084 | 16,084 | 16,084 | 16,084 | 16,084 |
| Net debt ($m) | 14,154 | 14,345 | 13,206 | 12,784 | 12,784 | 12,784 | 12,784 | 12,784 |
| Dow Inc. stockholders’ equity | 17,355 | 16,008 | 16,234 | 16,611 | 16,795 | 17,027 | 17,197 | 22,366 |
Source: FY24–FY25 Form 10-K; Penmark Research model.
| Per-share & ratio summary | FY24A | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E | FY35E |
|---|---|---|---|---|---|---|---|---|
| Weighted diluted shares (m) | 705.1 | 711.6 | 725.5 | 721.8 | 696.4 | 667.7 | 627.6 | 516.5 |
| Operating diluted EPS ($/sh) | 1.71 | −0.93 | 2.71 | 2.87 | 3.44 | 4.01 | 5.21 | 7.77 |
| Dividend per share ($/sh) | 2.80 | 2.10 | 1.40 | 1.40 | 1.40 | 1.55 | 1.81 | 3.37 |
| Free cash flow per share ($/sh) | −0.04 | −1.99 | 4.08 | 2.73 | 3.44 | 4.00 | 5.41 | 5.88 |
| Operating ROE (avg equity) | 6.7% | −4.0% | 12.2% | 12.6% | 14.4% | 15.9% | 19.1% | 18.5% |
| Operating ROA (net assets) | 3.1% | −1.7% | 4.9% | 5.3% | 6.2% | 6.9% | 8.4% | 9.2% |
| After-tax operating ROIC / ROCE | 6.3% | 1.0% | 9.0% | 9.4% | 10.3% | 11.2% | 13.1% | 13.5% |
| Net debt / Operating EBITDA | 2.58x | 4.41x | 2.10x | 1.99x | 1.88x | 1.77x | 1.59x | 1.36x |
| Gross debt / Operating EBITDA | 2.98x | 5.58x | 2.76x | 2.50x | 2.36x | 2.23x | 2.00x | 1.71x |
Source: Company filings; Penmark Research model (dividend rule: $1.40/sh floor or 45% of prior-year Op. EPS).
P&SP drives 68% of FY26E operating EBITDA as Dow completes a $6.3bn rebound year
| Quarterly & annual path | 1Q25A | 2Q25A | 3Q25A | 4Q25A | 1Q26A | 2Q26A | 3Q26A | 4Q26E | FY26E | FY27E |
|---|---|---|---|---|---|---|---|---|---|---|
| P&SP net sales | 5,310 | 5,025 | 4,891 | 4,744 | 4,919 | 6,385 | 5,778 | 5,800 | 22,882 | 21,939 |
| II&I net sales | 2,855 | 2,786 | 2,834 | 2,688 | 2,626 | 3,166 | 3,058 | 2,850 | 11,700 | 11,462 |
| PM&C net sales | 2,071 | 2,129 | 2,082 | 1,852 | 2,080 | 2,361 | 2,250 | 2,050 | 8,741 | 9,003 |
| Corporate net sales | 195 | 164 | 166 | 176 | 169 | 180 | 181 | 180 | 710 | 710 |
| Consolidated net sales | 10,431 | 10,104 | 9,973 | 9,460 | 9,794 | 12,092 | 11,267 | 10,880 | 44,033 | 43,115 |
| P&SP Operating EBITDA | 702 | 440 | 548 | 576 | 590 | 1,639 | 954 | 1,080 | 4,263 | 4,107 |
| II&I Operating EBITDA | 18 | −32 | 111 | −36 | 30 | 383 | 323 | 250 | 986 | 1,022 |
| PM&C Operating EBITDA | 249 | 344 | 254 | 199 | 298 | 291 | 299 | 260 | 1,148 | 1,424 |
| Corporate Operating EBITDA | −25 | −49 | −45 | 2 | −45 | −1 | −23 | −40 | −109 | −120 |
| Consolidated Op. EBITDA | 944 | 703 | 868 | 741 | 873 | 2,312 | 1,553 | 1,550 | 6,288 | 6,434 |
| Operating EBITDA margin | 9.0% | 7.0% | 8.7% | 7.8% | 8.9% | 19.1% | 13.8% | 14.2% | 14.3% | 14.9% |
| Operating diluted EPS ($/sh) | 0.02 | −0.42 | −0.19 | −0.34 | −0.14 | 1.44 | 0.71 | 0.68 | 2.71 | 2.87 |
| Local price / Volume y/y | −3%/+2% | −7%/−1% | −8%/−1% | −8%/−2% | −7%/−2% | n.a./−1% | +14%/−1% | n.a. | n.a. | −4%/+2% |
Source: Company quarterly releases and 3Q26 Form 8-K; Penmark Research model (n.a. = not available).
| Segment & operating KPIs | FY22A | FY23A | FY24A | FY25A | 9M26A | FY26E | FY27E |
|---|---|---|---|---|---|---|---|
| Segment net sales ($m) | |||||||
| Packaging & Specialty Plastics | 29,260 | 23,149 | 21,776 | 19,970 | 17,082 | 22,882 | 21,939 |
| Industrial Intermediates & Infrastr. | 16,606 | 12,538 | 11,869 | 11,163 | 8,850 | 11,700 | 11,462 |
| Performance Materials & Coatings | 10,764 | 8,497 | 8,574 | 8,134 | 6,691 | 8,741 | 9,003 |
| Consolidated net sales (incl. Corp.) | 56,902 | 44,622 | 42,964 | 39,968 | 33,153 | 44,033 | 43,115 |
| Segment Operating EBITDA ($m) and margin (%) | |||||||
| Packaging & Specialty Plastics | 5,506 (18.8%) | 3,985 (17.2%) | 3,856 (17.7%) | 2,266 (11.3%) | 3,183 (18.6%) | 4,263 (18.6%) | 4,107 (18.7%) |
| Industrial Intermediates & Infrastr. | 1,968 (11.9%) | 648 (5.2%) | 724 (6.1%) | 61 (0.5%) | 736 (8.3%) | 986 (8.4%) | 1,022 (8.9%) |
| Performance Materials & Coatings | 2,117 (19.7%) | 997 (11.7%) | 1,094 (12.8%) | 1,046 (12.9%) | 888 (13.3%) | 1,148 (13.1%) | 1,424 (15.8%) |
| Consolidated Op. EBITDA (incl. Corp.) | 9,348 (16.4%) | 5,389 (12.1%) | 5,482 (12.8%) | 3,256 (8.1%) | 4,738 (14.3%) | 6,288 (14.3%) | 6,434 (14.9%) |
| Archetype operating KPIs (Products & units, cyclical) | |||||||
| USGC / Global Hydrocarbons op. rate | n.a. | n.a. | n.a. | Low 80s | >90% / 83% | >90% / ~83% | >90% / n.a. |
| Incremental T2O / self-help ($m) | n.a. | n.a. | n.a. | 400 | ~500 | 700 | 1,105 (85%) |
| Cash conversion (CFO / Op. EBITDA) | n.a. | 96.4% | 53.2% | 32.6% | 90.5% | 86.9% | 71.8% |
| Trade working capital % of sales | 13.5% | 14.0% | 15.0% | 18.0% | 17.9% | 17.1% | 17.5% |
Source: FY25 Form 10-K Note 24 and 3Q26 release; Penmark Research model (Corporate EBITDA: −$243m / −$241m / −$192m / −$117m / −$69m / −$109m / −$120m).
GAAP-to-operating reconciliation, ratio definitions, cyclical methodology and data cut-off
| GAAP-to-non-GAAP reconciliation | FY24A | FY25A | 9M26A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|---|
| GAAP net income / (loss) attributable to Dow Inc. | 1,116 | −2,623 | 646 | 982 | 1,623 | 2,282 |
| Exclude: Significant items / after-tax restructuring | 90 | 1,961 | 829 | 985 | 449 | 117 |
| Operating net income attributable to Dow Inc. | 1,206 | −662 | 1,475 | 1,967 | 2,072 | 2,399 |
| Operating EBIT (segment sum, ex-significant items) | 2,588 | 422 | 2,689 | 3,569 | 3,707 | 4,100 |
| Add: Depreciation and amortisation (D&A) | 2,894 | 2,834 | 2,049 | 2,719 | 2,726 | 2,717 |
| Operating EBITDA | 5,482 | 3,256 | 4,738 | 6,288 | 6,434 | 6,817 |
| Free cash flow (continuing CFO less total capex) | −26 | −1,417 | 2,446 | 2,962 | 1,968 | 2,398 |
Source: FY25 Form 10-K, 3Q26 Form 8-K/10-Q; Penmark Research model.
Glossary of company & sector terms
Integrated PE margin (¢/lb): Margin per pound captured by cracking NGLs/naphtha into ethylene and polymerising into polyethylene; ~±$200m annual Dow EBITDA per ±1¢/lb.
Ethane advantage: Cost spread of US/Canadian natural-gas-derived ethane crackers (~25–28¢/gal) beneath European and Asian crude-oil-linked naphtha crackers.
MDI & alkoxylates: Methylene diphenyl diisocyanate (rigid/flexible polyurethane foams; ~40% housing-exposed) and specialty surfactants in II&I.
Siloxanes vs silicones: Upstream commodity siloxane monomers (oversupplied in China; Barry UK shut 2Q26) vs higher-margin downstream formulated silicones in PM&C.
Transform to Outperform (T2O): Restructuring programme (~4,500 roles, AI/automation & commercial growth) targeting ~$2.0bn EBITDA uplift by end-2027 ($0.7bn FY26, $1.2bn FY27 plus $0.1bn asset actions).
Path2Zero & APIP: Fort Saskatchewan, Alberta net-zero ethylene/PE expansion ($7.5bn gross capex, $6.2bn net after Alberta Petrochemicals Incentive Program [APIP] grants of about C$1.8bn [US$1.3bn], ~45% built; $1.0bn run-rate EBITDA by FY32E).
Sadara: 35%-owned Saudi petrochemical JV with Aramco; equity losses suspended 1Q26; $1,258m recorded negative investment & debt guarantee deducted in EV bridge.
Peer set
Primary valuation peer set: LyondellBasell (LYB, closest integrated polyolefins peer and 6.74x 13-year median EV/EBITDA anchor), Westlake (WLK), Eastman Chemical (EMN), Celanese (CE) and Huntsman (HUN). Global uncovered competitors (BASF, Covestro, Wacker, SABIC, Sinopec) are included in cost-curve, competitive and regression exhibits.
Ratio & valuation definitions
Operating EBITDA & FCF: Operating EBIT (ex-significant items, after operating lease expense) plus D&A; FCF = continuing CFO less total capital expenditures (one basis: deferred revenue $199m at Sep-26).
Operating ROE / ROA / ROIC (ROCE): Operating net income to Dow ÷ average stockholders’ equity (ROE); Operating net income to Dow ÷ average net invested assets (ROA); Operating EBIT × (1 − 22% op. tax) ÷ ending invested capital (equity + NCI + debt − cash).
EV definition: Full-bridge EV at $30.37 ($45,389m, used for all current multiples) = diluted market cap ($22,091m on 727.4m diluted shares; $21,984m basic) + net debt ($13,397m) + NCI at market ($3,439m = $2,943m InfraCo 49% + $496m book) + after-tax pension ($3.2bn), Sadara ($1.3bn), env./asbestos ($1.2bn) & remaining cash restructuring ($0.8bn), excluding the $2.0bn recovery-path wait-cost charge (present value of the after-tax profit shortfall below mid-cycle, 4Q26E to FY30E).
Methodology, situations & known limits
Archetype & situations: Products & units, cyclical, with leveraged/legacy-claims equity bridge and restructuring add-ons; ten-year explicit forecast to FY35E.
Conviction rating: Conviction is Low because lifting WACC by +1pt flips the rating to Hold ($26.93 target) and global-chemical high-end levered beta (1.60x) flips it to Sell ($24.31 target).
Limits & sources (cut-off 20 Nov 2026): Official close $30.37 (18 Nov 2026; 19 Nov $30.26 last trade not official close, −0.4%); SEC filings (FY25 10-K 3 Feb 26, DEF 14A 27 Feb 26, 3Q26 8-K/10-Q 22–23 Oct 26, Form 13F 30 Sep 26, Form 4 through Nov 26); exchange short interest (30 Oct 26); S&P Global consensus (Oct 2026); Yahoo Finance price/return series; environmental accrual could reach ~2.5x; $3.2bn other investments (insurance) conservatively excluded.
Analyst certification and important disclosures
Ratings
Ratings are based on the total return from the share price to our 12-month price target, including dividends. The price target is weighted across bull, base and bear scenarios.
| Buy | Total return to price target above +10% |
| Hold | Total return to price target from −10% to +10%, inclusive |
| Sell | Total return to price target below −10% |
We review ratings at each set of results and whenever the facts change materially. A share price can move outside its band before the rating changes, and targets may not be reached.
Analyst certification
The Penmark Team certifies that (1) the views in this report accurately reflect its views about the subject company and its securities, and (2) no part of its compensation was, is or will be directly or indirectly related to the specific ratings, price targets or views in this report.
Contact
Penmark Research
Questions about our research:
research@penmarkresearch.com
All our research and coverage:
penmarkresearch.com
Basis of preparation
This report uses information publicly available up to its publication date. Share prices are closing prices on the trading day before the publication date, unless stated otherwise. Forecasts, valuations and price targets are Penmark Research’s own, and forecast periods are marked E. Sources are shown beneath each exhibit.
Valuation and price targets
Price targets are based on the valuation methods set out in each report and are weighted across bull, base and bear scenarios. The main risks to each rating and price target are described in the report. Penmark Research updates its coverage after each set of results but is not obliged to update a report at any other time.
Independence and conflicts of interest
Penmark Research is independent. It does not provide investment banking, brokerage, market-making or asset management services, does not trade securities, and does not accept payment from any company for research coverage. Companies do not see or review Penmark Research reports before publication.
No member of the Penmark Team holds a long or short position, directly or through derivatives, in the securities of any company Penmark Research covers.
Regulatory status
Penmark Research publishes general, impersonal investment research on a regular basis. It is not registered as an investment adviser with the US Securities and Exchange Commission or any state securities authority, is not a registered broker-dealer and is not a member of FINRA. Penmark Research does not give advice tailored to any person’s circumstances.
Not investment advice or an offer
This report is for information only. It is not personalised investment advice and is not an offer or solicitation to buy or sell any security or other financial instrument. It does not take into account any reader’s objectives, financial situation or needs. Readers should make their own investment decisions and seek independent professional advice where appropriate.
Forward-looking statements and risk
Forecasts, valuations and price targets are estimates based on assumptions that may prove wrong, and they may not be achieved. Opinions are current as of the publication date and may change without notice. Investing in equities involves risk, including the loss of capital. Share prices can be volatile, and past performance is not a reliable indicator of future results.
Data and sources
Company financials, operating data and filings come from company filings, earnings releases and earnings calls. Market data and any consensus estimates come from third-party sources named beneath the relevant exhibit; consensus figures from aggregators are unofficial. Penmark Research does not use other brokers’ research. Third-party data belong to their providers and may not be extracted from this report.
Accuracy and liability
Information is taken from sources believed to be reliable, but Penmark Research makes no representation or warranty as to its accuracy, completeness or timeliness. To the fullest extent permitted by law, Penmark Research accepts no liability for any loss arising from use of this report. Descriptions of litigation and regulatory matters reflect allegations and public records, not findings, unless stated. If a published report is corrected, the corrected version carries an “Updated” date at penmarkresearch.com.
Distribution and access
Penmark Research reports are available to registered users of penmarkresearch.com. Downloads and programmatic access are governed by the Penmark Research subscription terms. This report is not directed at, or intended for, any person in Singapore or India, and access from those countries is blocked. It is not intended for distribution to, or use by, any person in any jurisdiction where that would be contrary to law or regulation or would subject Penmark Research to registration or licensing requirements there.
Copyright and permitted use
© Penmark Research. All rights reserved. Penmark Research is a trade name of Brightriver Labs. Readers may share a link to this report but may not copy, reproduce, redistribute, sell or use its content, including for text and data mining, without written consent. Contact: research@penmarkresearch.com.